Studies on interleukin-1-B-pre subpeptides by Maclean, Derek
Studies on InterIeukin-1--pre 
Subpeptides 
Derek Maclean 
A thesis submitted for the degree 
of Doctor of Philosophy 
University of Edinburgh 	 September 1991 
This thesis is submitted in part fulfillment of the requirements of the degree 
of Doctor of Philosophy in the University of Edinburgh. Unless otherwise 
stated the work described is original and has not been previously submitted, 
in whole or in part, for any degree at this or any other university. 
To my parents, 
Murdo and Helen, 
and to Stephanie 
Acknowledgements 
I would like to thank Prof. R. Ramage for the provision of research facilities 
and to gratefully acknowledge his constant advice and encouragement 
throughout the course of this work. 
I am very grateful to Drs. J.A. Eastgate and J.A. Symons and Prof. G.W. Duff 
for performing biological assays and for the many stimulating and helpful 
hours of discussion on the immunological aspects of this study. 
Sincere thanks are due to Mr. K. Shaw for technical assistance with the 
synthesis of the peptides described herein; Mr. B. Whigham for performing 
amino acid analyses; the academic and technical staff responsible for the 
running of NMR spectra; and all other members of the departmental technical 
staff for their support. 
Special thanks go to Dr. D.W. Thomas for proof-reading this thesis and for his 
helpful advice. 
I wish to thank the Science and Engineering Research Council for the 
provision of a research grant. 
Finally, I would like to thank all my friends and colleagues in Edinburgh for 
making my time here so enjoyable and productive. 
Abstract 
The synthesis of a series of a series of peptides from the processing region 
of interleukin-1- precursor (IL-1-13-pre) has been carried out using 
automated solid-phase methods. The subpeptide comprising residues 102-
138 was found to possess inhibitory activity towards the cleavage of lL-1-f-
pre in studies using human monocyte cell lines. 
Attempts have been made to define more closely the region of the peptide 
responsible for this activity. Overlapping dodecapeptides have been 
prepared which cover this region of the precursor. The highest level of 
residual biological activity was found to reside in the subpeptide 111-122, 
comprising six residues on either side of the site of processing. Various 
derivatives of this peptide have been prepared in order to enhance this 
activity. 
Several of these peptides have been investigated by high-field nuclear 
magnetic resonance (NMR). Complete assignment of the spectra of most of 
the dodecapeptides has been achieved. The NMR spectra of an analogue 
of IL-1--pre 102-138 where cysteine-124 has been replaced by alanine 
(Ala-124-IL-1--pre 102-138) have been obtained and partially assigned. 
Analysis of through-space interactions indicated that these peptides adopt 
random conformations. 
A survey of protecting groups for the side-chain amide functional groups of 
asparagine and glutamine in solid-phase peptide synthesis has been carried 
out. Novel dibenzosuberenyl-type derivatives have been prepared and 
successfully applied to the preparation of a series of peptides. A 
comparison between these derivatives and commonly used alternatives 
(unprotected amide, trityl and 4,4'dimethoxybenzhydryl) indicated that the 
trityl group was the most generally suitable means of incorporating these 
amino acids. 
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Chapter 1. Introduction 
1.1 The Immune System 
1.1.1 General 
The ability to repel invading organisms is a vital part of the physiological 
make-up of all members of the animal kingdom. Even the simplest 
invertebrates such as helminths (flukes and worms) or jellyfish possess 
elements of innate immunity (Latin immunitas, freedom from). They 
contain cells which are capable of delivering a bombardment of chemical 
weapons against an intruder. Higher animals have more complex immune 
systems which display adaptive methods for eliminating invaders. These 
systems are characterised by their ability to learn and adapt to their 
environment. Innate responses remain constant over time. The study of 
the mechanisms of immunity is called immunology, and many good 
textbooks give detailed accounts of the state of current knowledge (e.g. 
refs. 1 and 2). 
Immunology is moving fast in the light of the discoveries of cell and 
molecular biology in recent years. Techniques such as gene cloning and 
expression, and monoclonal antibody production have led to considerable 
advances in our understanding of the immune system. 
The work described in this thesis is an attempt to understand and ultimately 
control a pivotal step of the immune response. Before this can be 
discussed in detail some facets of the subject must be introduced more 
thoroughly. 
1.1.2 Innate Immunity 
The first lines of defence against infection are the body surfaces. Skin 
provides an effective physical barrier, and secretions generate an acidic 
environment in which most bacteria cannot survive. Broken or damaged 
skin is much more vulnerable. 
1 
The entrances to the body's internal surfaces are also closely guarded. 
Membranes produce mucus which traps foreign bodies, and reflexes such 
as coughing and vomiting help with the mechanical removal of invaders. 
Most bodily secretions such as tears, semen and saliva have antimicrobial 
properties. 
Despite these defences, infectious agents do sometimes succeed in 
entering the body where they can do real damage if left to multiply 
unchecked. Special cells are found in the tissues, which can bind to foreign 
particles and destroy them. Macrophages (Greek "big eater') engulf and 
digest their prey, whereas granulocytes expel chemicals which damage the 
invader. Complement proteins assist these processes by binding to foreign 
bodies and opsonising them, in other words enhancing their attractiveness 
to macrophages and granulocytes. These processes are relatively 
inefficient, and have been circumvented in many ways by various 
organisms.' 
1.1.3 Adaptive Immunity 
Innate immunity was for a long time thought to be a primitive method of 
protection but in fact it is the basis of the adaptive immune response. The 
cells and molecules of adaptive immunity merely serve to enhance the 
innate mechanisms. 
The adaptation is based on the ability of certain cells to respond to specific 
markers of foreignness and to selectively reproduce those cells which are 
best at dealing with the invader. The cells responsible are the small 
lymphocytes: B-cells which produce antibodies and T-cells which control 
the intensity and direct the effects of the immune response. 
Antibodies, or immunoglobulins, are the key molecules of adaptive 
immunity. They act in an analogous manner to the complement proteins in 
innate immunity, opsonizing invaders for disposal by other cells. They are 
however capable of exercising exquisite sensitivity in choosing the targets 
to which they bind. Each antibody binds to an antigen (antibody 
generator) which is part of a foreign body, e.g. a bacterial flagellum. The 
precise part of the antigen to which the antibody binds is called an epitope. 
Thus an antigen may possess several epitopes and be bound by several 
2 
different antibodies. B-cells carry antibodies on their cell membranes and 
so can recognise antigens. 






joined by disulphide bridges. 
e antigen-binding site is made up of 
regions of hypervariable sequence 
towards the N-terminus of each chain. 
Fig.1.1 the Fundamental Unit of Antibody Structure 
T-cells do not recognise intact antigens: the antigen must be presented by 
a particular type of macrophage in a form which the T-cell recognises. 
This is in fact the initial step in adaptive immunity. The 1-cell is stimUlated 
by antigen presentation and it in turn sends messages to B-cells and other 
T-cells to multiply and make ready to attack invaders. The ensuing 
cascade of activated cells ensures that the invader is overwhelmed before 
it can multiply. The messages referred to are delivered in the form of 
soluble proteins - the cytokines or "cell movers" 
1.1.4 Cytoklnes and Interleukins 
A cytokine3 is an inducible secreted polypeptide which affects the growth 
and function of cells. An lnterleukin 3 is a cytokine of known primary 
structure produced by leukocytes and active during the immune response. 
By the late 1970s around one hundred cytokines had been described and 
named on the basis of some observed in vitro or in vivo activity. With 








that single molecular species were often responsible for several of these 
effects. Rationalisation of the field has now reduced the number of 





b'I St Ce 
;/- 
2g < 
Fig. 1.2 Antigen-Selective Clonal Selection 
and Antibody Production 
Cytokines are now loosely classified into several families. The divisions are 
largely based on historical rather than well-defined scientific differences. 
The main cytokine families are the inter ferons 4, colony stimulating factors 5 , 
tumour necrosis factors6, and interleukins 7. The definition of an interleukin 
is so broad that many of the other cytokines, if discovered today, would 
probably be placed in this group. To date at least eight proteins have been 
so designated, interleukins 1 to 8 (IL-1 to -8). 
Most studies on cytokines have looked at their role in the immune 
response, but they may have important functions in homeostasis, growth, 
and development. They are important mediators of local cell 
communication (autocrine and paracrine) (see fig.i .3), but many may also 
.4 
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act in a systemic, hormone-like (endocrine) manner. One example of such 
a pleiotropic protein is the "endogenous pyrogen" interleukin-1. 
1. Autocrine 	2. Paracrine 	 3. Endocrine 
Fig. 1.3 Modes of Hormone Action 
1.1.5 Interleukin-1 
The wide range of properties of interleukin-1 is indicated by the number of 
separate names which it previously held (table 1.1). Its activity was first 
described by Atkins in 1955 8 as a protein which induced fever when 
injected into animals (endogenous pyrogen). The other names arose over 
the next 25 years. The present form, interleukin-1 was introduced in 1979 
at the 1st International Lymphokine Workshop held in Switzerland. Cloning. 




Endogenous pyrogen EP 8 
Lymphocyte Activating Factor LAF 9 
Leukocyte Endogenous Mediator LEM 10 
Mononuclear Cell Factor MCF 11 
B-Cell Activating Factor BAF 12 
Osteoclast Activating Factor OAF 13 
Synovial Factor SF 14 
Epidermal T-Cell Activating Factor ETAF 15 
Haemopoietin-1 HP-1 16 
Table 1.1 Previous Designations of lnterleukin-1 
5 
There are known to be many cellular sources of interleukin-1 but the major 
laboratory source is from monocytes (mononuclear phagocytes, of which 
the macrophage is an example). lnterleukin-1 is an inducible protein, i.e. 
only produced in the presence of certain stimuli. For example, when 
monocytes are treated with lipopolysaccharide (LPS, a component of 
bacterial cell walls) IL-1 activity is detectable intracellularly within 30 
minutes and outside the cell after approximately one hour 17 . On the 
timescale of the immune response this is extremely rapid (see fig.i .4). In 
fact IL-1 is thought to be the earliest cytokine produced on encounter with 
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Fig. 1.4 The Primary and Secondary Immune Response 
6 
Fig. 1.5 Selected Biological Properties of lnterleukin-1 
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1.1.6 The IL-11 Gene and Gene Products 
Murine IL-1 cDNA was first cloned in 198418 , and the human gene was 
identified soon after19-21 . March et al 22 identified and expressed two 
different human cDNAs encoding proteins with IL-1 activity which were 
designated lnterleukin-i-a and IL-1 -aand IL-1-). 






Fig. 1.6 Interleu kin-i Genes 
IL-1 -a and -0 show 26% homology of amino-acids but 45% at the nucleic 
acid level22. The organisation of the gene is identical in both cases, with 
seven exons and six introns. The two genes may well have arisen from a 
gene duplication event23 . Each cDNA codes for a protein of circa 31 kDa 
molecular weight (269 or 271 amino acids) although IL-1 activity had 
previously been mainly detected for a 17 kDa protein. It was shown that 
the 17 kDa species comprised the C-terminal region of the larger molecule 
in each case22, so it seemed probable that IL-1 -a and - gene products 
were precursors which were processed to the active forms. 
1.1.7 Receptors for IL-1 
The initial report of a specific IL-1 receptor was published in 1985 when 
Dower et a! 24  showed binding of radiolabelled IL-1 to munne T-cells. 
Further work estimated that there were approximately five hundred 
receptors per cell which bound IL-1 -a, IL-l-3 and the precursor to IL-1 -a ( 
IL-i-a-pre) with identical affinity (kM =10 -10 M) and kinetics but which did 
not bind IL-1--pre 25. This receptor has since been identified on several 
different cell types2627 and cloned from human 28 and murine29 T-cells. 
8 
The cDNA codes for a protein of 576 amino acids comprising three 
domains30 (see fig. 1.7). The cytosolic domain of this receptor has no 
recognisable enzymic activity 30. Any signal transduction via secondary 
messengers will probably involve another protein bound to this domain. 
Internalisation of IL-1 following receptor binding is also possible. Some 
intact IL-1 has been detected at the cell nucleus33 •34 as have IL-1 
receptors35. 
Notes 
i-ui: Three extracellular domains 
belong to the immunoglobulin 
superfamily30 . Presumably, resp-
onsible for ligand binding. 
iv: Intracellular domain may be linked 
to an additional effector protein31 ,32 
G :Glycosylation accounts for the 
observed variability in M.Wt27. 
Fig. 1.7 The 80 kDa IL-1 Receptor 
A distinct receptor was described by Matsushima et aP6 of 60 kDa 
molecular weight, reducible to 48 kDa on deglycosylation 37. This receptor 
has so far only been reported on B-cells. It shows a lower affinity for IL-1 -a 
than IL-1 - 13, both being less tightly bound than for the 80 kDa receptor. 
A third class of IL-1 receptor has been partially purified and 
characterised38. This has lower affinity for IL-1 than the 80 kDa receptor 
but binds IL-1 -13-pre  as well as mature IL-1-Il 
Like IL-1 itself, the IL-1 receptor is inducible (at least for the 80 kDa 
form).lts concentration at the cell surface is affected by stimuli such as 
LPS2739 .40 . Unstimulated cells bear very' low levels of IL-i r 24. This 
system is characteristic of several cytokines 41  and has been particulaily 
well studied in the case of interleukin-2. 
1.1.8 The Structure of Interleukin-1 Proteins 
In vitro IL-1-a and P mediate the same responses in all systems studied 
(though as we saw in section 1.1.7 the precursors do behave differently). 
As they can share the same receptor a comparison of their structures might 
be expected to indicate those areas of the molecules which are responsible 
for receptor binding and hence biological effects. 
Analysis of the primary structure of the two precursor molecules 22 revealed 
no strongly conserved regions of homology and hence little evidence for the 
position of shared functional domains. The main similarities were in fact 
found in the N-terminal region of the precursors, in the segment which is 
removed to give the mature proteins. 
The tertiary structure of the two proteins has also been investigated. 
Priestle eta! 42  reported the crystal structure determination of mature IL-i-
3 in 1988 and later refined their analysis to 2.0A 43. Nuclear magnetic 
resonance (NMR) spectroscopic analysis of a solution of mature IL-1 -P was 
in agreement with the solid-state structure 44. IL-1-3 is a compact globular 
protein containing twelve 13-strands which form a barrel-like structure; The 
overall folding pattern is very similar to that of soybean trypsin inhibitor 45 , 
and correlated well with structure predictions based on circular dichroism 
(CD) and fluorescence measurements46 . 
FIg.1 .8 Interleukln-1 -13 Structure 
10 
The crystal structure of mature IL-1 -a was solved in 1990. The overall 
shape of the molecule is identical to IL-1-0, again taking up the 13-barrel 
conformation (the "IL-1-fold" 47). The N-termini of the two mature proteins 
are positioned differently. This may offer an explanation of the differential 
activity of the precursor molecules. Some functional region of IL-1-13 may 
be hidden by the additional residues in the precursor whereas the 
homologous region of IL-1-a-pre may be available for receptor binding. 
CD studies on lL-1-3-pre have been carried out 48 and indicate that this 
protein has some a-helical character. It seems likely that the additional 116 
N-terminal residues form a new domain. 
Comparison of the tertiary structures reveals little more on the question of 
functional sequences. Most of the conserved residues lie in the 
hydrophobic core of the respective molecules where they are not available 
for interaction with the receptor. 
Various other techniques have been applied to the problem of identifying 
functional areas of IL-1. Point mutations have been introduced at various 
positions in the IL-1 gene but in most cases both folding and biological 
activity remained unchanged4 49. Histidine-30 of IL-1-13 was shown to be 
important in stabilising part of the protein structure 50 , and replacing 
arginine-127 with glycine reduced bioactivity 51 . Truncated IL-1 molecules 
have been tested showing that the loss of more than a few residues from 
either terminus considerably reduces the function of both IL-1 -a and ..1352-4. 
This is probably due to disruption of the IL-1 fold 55 . 
1.1.9 IL-1 Production 
Regulation of IL-1 levels is a possible mechanism by which the in vivo 
immune response is controlled. There are many potential steps leading to 
IL-1 production at which this control could be exerted (see figure 1.9). 
11 
IAg D Ab  RNA polymerase ribosome 
fl L  pre 
PRUNNA 
3 Protein Synthesis 
Secondary Messengers 	 4 Protein Processing 
mRNA Synthesis 	 5 Secretion 
Fig. 1.9 IL-1 Production 
LPS-induced IL-1 production is blocked by actinomycin and cycloheximide 
indicating de novo RNA synthesis 17. Also IL-1-0 mRNA is produced more 
quickly and to a higher level than IL-1-a mRNA 17. Thus some control is 
exercised at the transcriptional level. Analysis of the IL-1 genes has 
identified several potential promoter motifs and other regulatory sites 23 . 
Possible transcriptional activator23 and suppressor56 proteins have been 
identified. It has been reported that transcription of the IL-1 gene may 
occur without induction of protein synthesis57. This may be a result of post-
transcriptional modification affecting the half-life of the resultant mRNA 58 . 
IL-1 must be secreted from the producing cell in order to have biological 
effect, but unlike most secretory proteins 60 no form of IL-1 has a 
recognisable signal sequence. The kinetics of IL-1 secretion are unusual 61 
and there is some evidence that an alternative mechanism of exportation 
12 
may operate 62. Several other proteins have also been identified as non-










A: most secreted proteins are 
exported (i)via the endoplasmic 
reticulum. A hydrophobic signal 
sequence helps passage through 
the membrane and is cleaved at 
the same time. Other post-
translational modifications such as 
glycosylation (G) are also carried 
out at this stage. 
B: proteins lacking a signal 
sequence have been postulated as 
being exported by two methods: (ii) 
membrane-bound proteolytic activity 
releases part of the protein to the 
supernatant; or (iii) the protein is 
enclosed in a vacuole; This fuses 
with the membrane expelling the 
protein. 
Fig 1.10 Secretion of Proteins 
The IL-1-13 gene has been transfected into a rodent cell-line and 
engineered such that the precursor protein was constitutively produced 64 . 
No extracellular IL-1 activity was detected. It would appear that the ability 
to secrete IL-1. is specific to those cells which normally produce it. 
Cell death and lysis have been postulated as alternative pathways for IL-1 
release65 but studies of IL-1 -producing cell cultures, have failed to identify 
13 
other cytosolic proteins66 which would be expected to escape if such a 
passive route was used. 
The final link in the chain of events leading to IL-1 production is the 
proteolytic processing of the IL-1 precursor molecules. Studies in this area 
have largely concentrated on IL-1-0, following the observation that IL-i-a-
pre was active and bound to the T-cell (80 kDa) receptor 25 . 
The site of IL-1 -p-pre cleavage in monocytes was characterised by 
Cameron et ai67 (see figure 1.11). Subsequent studies 6870 have 
characterised several products of IL-1 -p-pre proteolysis of approximately 
the same size as mature IL-1-13. None of these gave full IL-1 bioactivity 
though in general the closer to the correct cleavage the more active the 
product. It was therefore suggested that there was a specific protease 
which cleaved IL-1 -p-pre to give the fully active protein. However the fact 
that other proteolytic activities could give considerable IL-1 activity again 
raises the question of the nature of the secreted form of IL-1. Though the 
in vitro evidence suggests that secretion and processing events are active 
and specific for IL-1-P66 it cannot be ruled out that in vivo cell lysis and 
non-specific cleavage is a major route for the generation of IL-1 activity, 
indeed it is possible that incorrectly processed IL-1 is a characteristic of 
certain disease states. 
Cathepsin G 
Trypsin 	Elastase 	Elastase 	Mature IL-1-13 
0.02% 15% 20-70% 100% of activity 
KLRJML ...... PIFFDTWDNEA)VHDVRSLN.... 
7677 	103104 	 113114 116117 
Fig. 1.11 Proteolysis of IL-1-13 
Recently workers at Merck71 in the U.S. have succeeded in partially 
purifying an lL-1-3-converting enzyme (which they have called ICE) which 
cleaves the IL-1P precursor at the correct point for full biological activity. 
This enzyme is located in the cytosol of monocyte and monocyte-like cell-
lines. The specificity of ICE has been investigated by these workers 71 and 
14 
by a team from the Immunex Corporation of Seattle 72 .73 . The results are 
summarised in fig. 1.12 and show that the enzyme is highly selective with 
regard to the primary sequence of the substrate. 
	
Peptide 	 Rate of 
Substrate Cleavage 
AYVHDAPVRS 	 1.00 
N 	 <0.01 
E <0.05 
D* 	 <0.01 
G 3.40 
V 	 <0.05 
F 	 0.50 
A 	 0.47 
H D A P not cleaved 




Fig. 1.12 Substrate Specificity of ICE 
When the precursor to IL-1-0 was denatured by heat, specific cleavage still 
occurred73. This .and the fact that relatively short synthetic peptides are 
also substrates suggests that the overall tertiary structure is of little 
importance to the enzyme activity. The sensitivity of the enzyme to peptide 
length does suggest that elements of local secondary structure may be 
important. The convertase has not yet been fully purified and very little 
characterisation data has been published, though it has been reported to 
be a member of the serine protease family. 
15, 
1.1.10 Modulators of IL-1 Activity 
As IL-1 is such a key mediator of the immune response it would be 
expected that its level would be carefully regulated in vivo. Control at the 
various steps of production was discussed in the last section, but there is 
also a need for post-production control mechanisms. These generally 
control the effective concentration of IL-1 by altering protein/receptor 
interactions. Blocking of IL-1 receptor-binding may be achieved by 
molecules which have affinity for either IL-1 or its receptor 74 . 
1.1.10.1 IL-i Receptor Antagonists 
IL-1 antagonist activity has been observed from a number of sources for 
instance the urine of febrile patients7576,synovial fluid 77, virus-infected 
cultures78,or UV-treated biological samples 79. In most cases the nature of 
the inhibitory species has not been determined, but in two cases the activity 
has been characterised. Seckinger eta! 80 isolated a protein from the urine 
of patients with moncytic leukaemia and showed that it competed with IL-1 
for binding sites on a T-cell clone. 
More recently Hannum et a! 81  identified three monocyte-de rived IL-1- 
receptor antagonist proteins (IL-ira or IRAP) which turned out to be 
differentially glycosylated forms of the same protein. All three species 
bound equally well to IL-1 r-bearing cells with a similar affinity to both forms 
of mature IL-1. Cloning of the IL-1 ra gene 82 indicated that the protein was 
related to IL-1-a and - (19 and 26 % amino-acid homology; similar gene 
organisation) though it possessed a recognisable signal sequence (hence 
the glycosylation). The protein showed no IL-1 agonist activity in several 
recognised assays. 
It was later shown that this IL-1 ra did not bind to B-cells 83 , nor did it show 
antagonist (or agonist) activity in another assay. This fits well with the 
results discussed in section 1.1.7 indicating the existence of distinct classes 
of IL-1 receptors. It also suggests that different parts of the IL-1 molecules 
may be responsible for different biological effects. 
Once again most conserved residues between this IL-i ra and the two 
forms of IL-1 lay in the hydrophobic core, but Eisenberg et a! 82 showed 
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that the C-terminal region had a similar hydrophobicity plot to the 
analogous region of IL-1-13. A synthetic peptide comprising part of this 
sequence, IL-1-P-233-269 (the C-terminal 33 residues of both IL-1-0 and its 
precursor) prevented thymocyte activation when present in an IL-1 assay at 
micromolar levels 84 . 
Other studies with shorter peptides 8586 have shown antagonist activity but 
only when present at high concentrations in unusual model systems. The 
exact nature of the inhibition in these reports was not investigated. 
1.1.10.2 IL- i-Binding Proteins 
Uromodulin is a glycoprotein found in the kidney and urine which has been 
shown to bind IL-1 87. Its location suggests that this may be a mechanism 
for the excretion of IL-i 88 . The major source of elimination of administered 
radiolabelled IL-1 has been shown to be via the urine. 
Soluble forms of cytokine receptors have been known for some time, and 
have been shown to compete with the membrane-bound receptor for 
ligand89 , thus exerting inhibition of the ligand's effects. A protein of this 
type was recently identified which derives from the 80 kDa IL-1 r by 
proteolytic cleavage on the extracellular side of the membrane-spanning 
domain. This soluble form of the IL-1 receptor (slL-i r) shows unchanged 
binding properties to intact IL-1 r90 . 
Autoantibodies to IL-1 -a have been detected in healthy individuals 91 . It is 
not clear what effect this has on biological activity. Anti-interferon-1 has 
been administered together with interferon-1 with no loss of anti-viral 
activity92. It seems possible that such binding proteins protect cytokines 
from degradation. 
Such a role has long been suggested for a 2macroglobulin, a serum protein 
which binds other active proteins93 . The binding of IL-1 to this protein has 
been shown to accompany resistance to proteolysis 94 . 
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1.1.11 Pathological and Physiological Roles of IL-1 
Most studies on the biological properties of IL-1 have focussed on its role in 
adaptive immunity, and this is indeed a key function of the molecule. 
Analysis of IL-1 genes in various species indicate that the molecule 
appeared somewhat before lymphocytes and antibodies in evolutionary 
history95 , suggesting a more fundamental role for IL-1. 
Inflammation is the main evidence of an in vivo immune response. Four 
main things happen to cause this state: 
-blood supply to the affected area is increased; 
-increased permeability of capillaries allows soluble immune 
mediators to reach the site; 
-leukocytes migrate towards the site of infection; 
-local or body temperature rises (fever). 
These are all innate processes, and all are known to be IL-1 dependent 96 . 
They ensure the optimal ability of the body to respond to invasion by 
foreign organisms. 
An ideal immune response would restore the full function and integrity of 
the site of infection, but inflammation has a fundamentally dualistic nature - 
the repair process is accompanied by undesirable side-effects including 
attack on healthy tissue and excess tissue deposition. This is normally of 
little importance and a small price to pay for the protection of the rest of the 
body, but several disorders are characterised by inappropriate and 
damaging immune responses. 
Allergies such as hay-fever result from an over-zealous response to a 
relatively inoccuous allergen (pollen granules). A similar, if rather artificial 
effect is observed in organ transplantation and tissue grafts in general. The 
recipient displays immunity to the graft to a greater or lesser extent 
depending on the apparent "foreignness" of the donated tissue, resulting in 
graft rejection. If substantial numbers of leukocytes are present in the 
transplanted tissue they can mount an immune response against the 
recipient. This graft-versus-host reaction can prove fatal. 
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Ab 
macrophage 	- 	T-celI 
Notes 
1 Recognition of antigen results in the production of immune mediators 
such as IL-1. 
2 T-cell activation results in the production of further soluble immune 
mediators. 
3 Endothelial cells retract allowing effector cells to leave circulation and 
move towards the site of infection. 
4 B-cell activation initiates antibody production. 
5 Soluble immune mediators enter the bloodstream with local and hormonal 
effects 




More common and probably more damaging to society are the autoimmune 
diseases. This class of disorders are characterised by prolonged and 
harmful immune response in the absence of detectable infectious agents. 
Many diseases fit this pattern, e.g. juvenile (type-1) diabetes, pernicious 
anaemia, thyroiditis and many others 97. Mechanisms which have been 
suggested97 for these illnesses include the breakdown of intercellular 
communication, the production of abnormal antibodies and the excess 
production of pro-inflammatory mediators 98, of which IL-1 is a prime 
suspect. The role of IL-1 in many such diseases has been reviewed by 
DiGiovine and Duff99. One particularly prevalent and well-studied 
autoimmune disease is rheumatoid arthritis. 
1.1.12 IL-11 and Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a disease characterised 100 by chronic 
inflammation of the synovial membrane of articulated joints. The resulting 
damage done to neighbouring cartilage and bone leads to severe 
curtailment in the use of the joint. Systemic features are also observed, 
such as fever, muscle wasting and weight loss. 
It had long been suspected that IL-1 might be important in RA since many 
of the cytokine's in vivo and in vivo activities mirrorred RA symptoms. 
Endogenous pyrogen activity was detected in synovial exudates in 1967 101 , 
and other factors from table 1.1 were identified in the same fluid 102103 . 
The discovery of the common identity of these factors led to attempts to 
correlate the level of IL-1 with disease activity. Most early studies proved 
inconclusive because assays depended on measuring IL-1 bioactivity. 
Interfering factors in complex clinical samples made results impossible to 
assess quantitatively98. Furthermore, IL-1-a and - 13 behave identically in 
such analyses. 
The advent of immunoassay has permitted quantitative determination of 
both forms of IL-1 104,  and application to RA has proved notably fruitful. 
High levels of IL-1 -a and - 13 have been detected in RA synovial fluid105 . 106 , 
with the concentration of the 0 form being approximately ten-fold higher 
than that of the form. This relationship has been independently observed 
in most studies2295 and also holds for mRNA levels. The reason for the 
differential production of the two forms is unclear, as are the biological 
consequences. 
Measurement of IL-1 -0 concentration in the plasma of RA patients revealed 
significant correlation with Ritchie joint score (a measure of joint movement) 
and several other indicators of disease state 107 . The level of IL-1-13 in 
individual patients varied dramatically over a period of several weeks, being 
typically high on admission to hospital (corresponding to a flare-up in 
stiffness and pain), falling steadily as the symptoms declined, then often 
rising again 107 . The correlation of serial measurement of IL-1-0 with 
Ritchie score is shown in figure 1.14 
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Fig 1.14 Correlation of IL-1-3 and Ritchie Score 
The level of IL-1 -a detected in these studies was, typically, one order of 
magnitude less than the level of lL-11-3, and only a low correlation with RA 
symptoms was observed. 
These results do not provide evidence for or against a causative role for IL-
1-3 in RA, but indicate that elevated IL-1 release is pathogenic independent 
of its place in a chain of events leading to clinical disease. 
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1.2 Solid-Phase Peptide Synthesis 
1.2.1 General 
Peptides were originally defined as being derived from the digestion of 
proteins. The name "protein" reflects the recognition of the crucial 
importance of these compounds to biology. Proteins are responsible for 
the structural integrity, homeostasis, growth and proliferation of all 
organisms on earth. Even the replication and translation ofthe genetic 
message, though carried by nucleic acids, is under the control of proteins. 
The terms peptide and protein are not mutually exclusive 	Mature 
interieukin-l-P is by definition both a peptide and a protein. Generally a 
peptide is of low molecular weight, though again "low" is open to 
interpretation. One hundred residues is a generally accepted cut-oft point. 
The problem is really one of semantics and not biology. 
Solid-phase peptide synthesis (SPPS) is one of several "chemical" methods 
for making peptides 108, and there are many other "biological" routes to 
obtaining these useful molecules. 
SPPS was conceived by Merrifield in 1959 109 and has gone on to become 
the predominant chemical means of producing peptides. Successful 
application of this advance could not have taken place without a thorough 
understanding of the principles of peptide synthesis, a science already 
almost 60 years old at the conception of 5pp5110 
1.2.2 Principles of Peptide Synthesis 
The smallest peptide comprises two alpha-amino acids joined by an amide 
bond (1). All proteins contain amino acids linked in this manner. 
H3N)(* N 
\Q }R' (1) 
Fig. 1.15 A Dipeptide With the Peptide Bond Indicated 
A mixture of two amino acids and a coupling reagent reacts in a random 
manner to give a complex mixture of products. Many of the amino acid 
side-chains carry functional groups (e.g. 7 and 8) which may also react, 
increasing the number of possible products. 
RI 
HNCOO + HNCOO 
(2) 
	 coupling 	(3) 
reagent 
R' H 	 R 2 H 	 R 1 H 
oo -  H;N(Ny coo- c 
	
+ HN N 	+ HN N COO 
(4) 
0 	R 2 	 0 	R' 	 (6) 0 	R 1 
+ other dimers, trimers,and higher polymers 
Fig 1.16 Ambiguity in Coupling Amino Acids 
+ 
H * N 	coo - 
lysine  
coo- 
(8) ( J 
HN C00 
glutamate 
Fig 1.17 Amino Acids With Side-Chain Functionality 
Nature manages to assemble proteins from their constituent monomers in 
an unambiguous manner, but chemists have to protect certain parts of 
reagent molecules and activate others to achieve the desired result. Fig. 
1.18 shows a scheme for preparing a dipeptide using amino acids 7 and 8. 
993 
	
NH-PG 2 	 NH-PG 3 
0 0-PG3 
(9) 	 + 	(10) 	 (11) 
NH OACt 
H2N P G PG1NH N - 
0 	 0 L04 
PG1 
PG1-4 = protecting groups; Act = activating group 
kG3  
Fig 1.18 Unambiguous Coupling of Lysine and Glutamic acid 
Activation of the carboxyl component is achieved by replacing the hydroxyl 
group with an electron-withdrawing substituent. These will be discussed in 
section 1.2.4. There is no good method for activating the amine 
component. 
In order to produce peptides containing three or more amino acids the 
nature of the protecting groups must be considered in more detail. One of 
the termini of the dipeptide must be freed whilst leaving all other protecting 
groups intact. For a number of reasons which are discussed in section 
1.2.3 it is usually best to remove the protection on the a-amino group. 
Temporary N°.-protection is dealt with in section 1.2.5 and semi-permanent 
protection in section 1.2.6. 
1.2.3 Strategy of Peptide Synthesis 
Three possible routes to a tetrapeptide are shown in figure 1.19. Assuming 
that the yield for each coupling is 90%, then the overall yield of ABCD in 
strategy i) (fragment condensation) is 81% as opposed to 73% in either 
strategy ii) or iii)(stepwise condensations). 
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AB 	CD 	 CD 	 AB 
AB + CD 	 B+CD 	 AB+C 
ABCD 	 A+BCD 	 ABC +D 
ABCD 	 ABCD 
Fig. 1.19 Strategies for Tetrapeptide Synthesis 
For the octapeptide ABCDEFGH the corresponding yield in a strategy i)-
type scheme is 73% and only 48% in the other two cases. It would seem 
that fragment condensation methods are fundamentally better. However 
some chemical aspects must be considered. 
It can be seen that strategies i) and iii) require the activation of the carboxyl 
terminus of a peptide fragment. By contrast, the active species in strategy 
ii) will be a Naprotected  amino acid. This is of crucial importance because 
racemisation can take place. 
Racemisation occurs principally via proton abstraction following 
5(4H)oxazolone (14) formation (fig. 1.20) from the activated derivative, and 
this is suppressed when suitably protected amino acids (section 1.2.5) 
(rather than peptides) are activated. This is a major reason why strategy 
ii), C-.N stepwise condensation has become the most common method for 
chain assembly. 
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(12) H N 	 N - (o 









B - 	(15) N( 
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(16) N( 	I 
.4 	. 
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R 	 J 
Fig 1.20 Racemisation via 5(4H)Oxazolone 
1.2.4 Activation and Coupling Methods 
Many different methods for activating carboxyl groups have been applied in 
peptide chemistry 111 . The general form of an activated amino acid is 
shown in fig 1.21. 
(17) 
PG-N H 
Fig 1.21 An Activated Amino Acid. 
The group X should be electron-withdrawing, rendering the carboxyl carbon 
more electrophilic. The stronger this polarisation, the faster the coupling 
will proceed. However, strong activation also favours racemisation by an 
analogous pathway to fig 1.20. An efficient coupling method should not 
overactivate the carboxyl group. Amino acid chlorides were used in one of 
the very first attempts at peptide synthesis 112 , but successful applications 
have been extremely limited because the activation they provide is too 
powerful. 
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Acid azides (18) 113 have retained favour as coupling agents for somewhat 
longer. Their more gentle activation normally gives negligible racemisation, 
though a troublesome side-reaction (fig 1.22) means that careful 
precautions must be taken in their usage. 
o (18) 	 (19) 
+ - _ 	R-N=C=O + N 2 
N=N=N 
R'-NH 2 	 R'-NH 2 
IF 
0 
R 	R' 	 R- 	R' 
N 
H (20) 	 0 	H (2 1) 
Fig. 1.22 The Curtius Rearrangement 
Various anhydrides have been used with some success. Several reviews 
of this method have been published 114 . Examples of mixed anhydrides 
which have been successfully applied are shown in fig 1.23. 
Ref. 
(17): X= 	(CH3)2CHCH2CO2- 112 
(CH3)3CCO2- 113 
R 
1 	C2H500O2- 114 
PG-NH 	 'f (PhO)2P02- 115 
X 	(Ph)2P02- 116 
Fig 1.23 Mixed Anhydrides For Peptide Synthesis 
Considerations of regioselectivity, important in the mixed anhydrides 
become irrelevant if the symmetrical anhydride of each amino acid is used. 
These give good activation with little racemisation and have found 
widespread use. They can be conveniently prepared by treatment of 
protected amino acids with reagents such as dicyclohexyl- 120 or 
diisopropylcarbodiimides 121 . 
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PG-NH ° NH-PG 
Fig 1.24 Symmetrical anhydride of amino acid 
Esters of amino acids have only one activated carbonyl group and thus also 
give unambiguous acylation of the amine component. The activation 
provided in these cases is distinctly less than in anhydrides but this 
minimises racemisation and some other side-reactions. N-
Hydroxysucci ni mide(23)1 22,  pentafluorophenyl (25) 123 and 1 -hydroxybenzo-












Fig 1.25 Hydroxy Components of Active Esters 
1.2.5 Ne-Protecting Groups 
The main requirements for Naprotecting groups were introduced in 
sections 1.2.2 and 1.2.3, viz: 
-they must be easily removable in conditions which leave other 
protecting groups and all peptide bonds intact; 
-they must prevent acylation at the protected amine 
-they must prevent the activated amino acid from racemisation. 
Various Naprotecting groups are discussed in ref 125. 
The urethane group (26) was recognised as a good potential Naprotecting 
group very early in peptide synthesis. These derivatives decrease the 
nucleophilicity of the a-nitrogen and hence minimise racemisation via 
oxazolone formation (see fig. 1.20). Initial cleavage of the urethane ester 
linkage results in formation of a carbamic acid (27) which spontaneously 
decarboxylates to the free amine (fig. 1.26) 
	
ROAN 	 No HON 	 H2N 
(26) 	 (27) 	 (28) 
Fig. 1.26 Urethane Cleavage 
The first practically applicable urethane Naprotection to be introduced was 
the benzyloxycarbonyl or Z group (29) 126 which can be removed by either 





N 	 + CO2 + H 2 N 
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H  
No- 6 + c02+ H2N° 
Fig. 1.27 Removal of Z group 
Tertiary butyloxycarbonyl (Boc) derivatives (32) were the prototypic highly 
acid-labile urethane Naprotected amino acids 127. The sensitivity to acid 
arises because of the stable t-butyl carbocation which is produced (33). 2-
(4-Biphenyl)propyl(2)oxycarbonyl (Bpoc) derivatives (34)128  are even more 
acid-labile. The Z group is stable under the conditions for cleavage of these 
groups, thus allowing the use of benzyl-derived side-chain protection with 
Boc Naprotection. 
0 R 	 R 
H + 	
+ + H N ) 
o 
2 	2	"'f 
(32) 	H 	 (33) 	 (28) 
0 R 
(34) 	 0 	N 
Fig. 1.28 Acid-Labile Urethanes 
Urethanes are also available which readily lose a proton to give a stabilised 
anion. These are déprotected under basic conditions via 3-elimination. 
Foremost among this class are the 9-fluorenylmethoxycarbonyl (Fmoc) 
derivatives (35)129 
0 R 	 0 R 
N 	
base 
0 N )y 
H 0 	 6) H 0 
02CNH 	 CO2 + H 2 N 
g(37)
0 
(27) ° 	 (28) 
Fig. 1.29 Cleavage of Fmoc Group 
30 
This base-lability offers a further dimension for peptide chemistry since true 
orthogonality can be achieved in the conditions required for cleavage of the 
Na- and side-chain protecting groups. 
1.2.6 Semipermanent Protecting Groups 
Up to this point only generic aspects of peptide chemistry have been 
discussed. No account has been taken of the diverse nature of individual 
amino acids. The different side-chain functional groups may sometimes 
affect the choice of coupling method or Nd_protection, but most generally 
applied techniques work well with all amino acids. 
The specific properties of each amino acid must be taken into account in 
the choice of semipermanent side-chain protecting groups. The 
requirements for protection are shown in table 1.2. 
Extensive reviews of side-chain protecting groups in peptide synthesis are 
available 130 and a review by Bodanszky and Martinez gives a clear insight 
into the individual nature of each amino acid 131 
1.2.7 The C-terminus: The Solid-Phase Principle 
The C-terminal carboxyl group is chemically very similar to side-chain 
carboxylic acids, and was most often protected in an identical manner 
though orthogonal protection was available if required 108 . 
In 1963 Merrifield introduced a new C-terminal "protecting group" in the 
form of a functionalised insoluble polymer, chloromethyl polystyrene 
crosslinked with a small amount of divinylbenzene 109. This resulted in him 
being awarded the Nobel prize for chemistry in 1984 1 . 
The process  was designed to combat some fundamental problems faced 
by solution-phase methodology, namely the extremely difficult and time-
consuming process of purifying intermediates and the poor solubility of 
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Table 1.2. Side-Chain Protection Requirements 
Following attachment of the C-terminal amino acid to the polymer, chain 
assembly takes place towards the N-terminus, with all excess soluble 
reagents and by-products being removed by filtration and washing of the 
peptide-"resin". Treatment with acid then gives the desired peptide. 
Merrifield's classical SPPS scheme is shown in fig 1.30 and the modified 
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Fig 1.30 Merrifield Solid-Phase Peptide Synthesis (SPPS) 
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Fig. 1.31 Modified SPPS 
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These protocols confer several practical advantages over solution-phase 
syntheses: 
-purification of intermediates is eliminated 
-reactions can be driven to completion by the use of excess 
reagents 
-vessel transfer is eliminated thereby minimising mechanical 
losses 
-automation is possible. 
These advantages have led to the development of peptide synthesiser 
machines which can automatically assemble protected peptide chains from 
suitably derivatised amino acids, greatly easing syntheses. Mernfield's 
introduction of SPPS is arguably the biggest single advance in the history of 
peptide synthesis. Many more and longer peptides could be produced and 
applied to research into biological processes. This method of peptide 
synthesis is now by far the major means for producing these important 
molecules. 
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Chapter 2. Discussion 
2.1 Study Aims 
The following observations are a summary of the pathophysiological role of 
interleukin-i and the reasons for the considerable academic and industrial 
interest in this cytokine. 
Inflammation can become damaging if uncontrolled for some 
reason, e.g. in rheumatoid arthritis and other autoimmune diseases. 
IL-1 is the earliest detected mediator of the immune response. 
Observed IL-1 activities match the damaging effects of 
inflammation. 
IL-1 levels show positive correlation with the seventy of a number 
of disease symptoms. 
IL-1 activity may be controlled by a complex set of mechanisms, at 
the level of transcription, translation, processing and receptor 
binding. 
Based on these observations we have set out to gain an insight into IL-1 
production and regulation, and to try and modulate IL-1 activity with a view 
towards identifying potential anti-inflammatory actions. 
The difference between the two forms of IL-1 has been a topic of much 
debate for some time. IL-1 -a and -P behave identically in all assays which 
have so far been described, and are produced in response to the same 
stimuli. It might therefore be expected that only one such protein would be 
needed to mount a mature immune response, and that the other form would 
have been lost in evolution. 
This pairing system is not unique in cytokine biochemistry. The two tumour 
necrosis factors TNF-ct and 3134  are structurally related proteins which 
share the same receptor and apparently identical biological properties. The 
TNFs have many functional homologies to IL-1 and are also produced very 
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early in the immune response. It is interesting that these related proteins 
should have such similar organisation. 
Other cytokines also appear to show this pairing homology35. It appears to 
be a conserved feature of the evolution of this class of proteins, though the 
driving force remains unclear. 
Several mechanisms can be conceived of as to why two IL-is are better 
than one. Firstly it may act as a fail-safe. If each IL-1 is independently 
capable of eliciting an effective immune response then even if one system is 
eliminated or eluded the other will still protect the body. Secondly the fail-
safe could serve to protect the body's own tissues from the damaging 
effects of inflammation by only mounting an immune response when both 
signals were received. Thirdly the double system may somehow accelerate 
the onset of the immune response thus clearing invading organisms more 
quickly. Some combination of these and other reasons may provide the 
driving force for the conservation of two IL-is. 
One important difference between IL-1 -a and -13  is in the activity of their 
respective precursor molecules, the precursor to IL-1-cc being an IL-1 
agonist and binding to IL-1 receptor whilst IL-1-f3-pre is inactive and does 
not bind the receptor. Thus inhibiting the proteolytic processing of both IL-
is would remove IL-1 -P activity but leave IL-1 -a activity. It is probable that 
both forms of IL-1 &re cleaved by separate, specific enzymes as there is 
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IL-1 -a-pre 101-124 
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IL-1 -p-pre 105-128 
Fig. 2.1 The Cleavage Regions of IL-1-a and -13 
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Hence it should be possible to design agents which will selectively prevent 
the processing of IL-1-13, offering the possibility of studying an immune 
response in the absence of this protein. This would be a useful step 
towards an understanding of the in vivo immune response. 
Our approach to the design of ICE inhibitors (interleukin-1-13 converting 
enzyme) was set out in two stages. Firstly synthetic subpeptides of IL-1 - P  
were to be prepared in an effort to find those parts of the precursor 
molecule which were involved in interaction with the enzyme. Secondly, 
chemical modifications would be introduced in the most important of these 
subpeptides to produce tight-binding inhibitors of the enzyme. The work 
presented in this thesis relates entirely to the first stage of this programme. 
2.2 Synthesis of IL-1--pre Subpeptides 
2.2.1 Initial Target 
The initial aim was to make a peptide which contained the cleavage site of 
IL-1 -p-pre and included a similar number of residues on either side of it. 
The peptide should be of sufficient length such that it may be expected to 
possess secondary structure similar to that region of the natural precursor, 
and hence be likely to interact with the processing enzyme. 
The sequence of this first peptide and its relationship to mature IL-1 -0 and 
IL-1 -f3-precursor are shown in fig. 2.2. 
2.2.2 Peptide Synthesis 
The principles of solid-phase peptide synthesis are described in section 1.1. 
The general strategy employed in the synthesis of all lL-1-3-precursor 
subpeptides described here was the orthogonal protection scheme 
(modified Merrifield SPPS) as shown in fig. 1.31. 
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Precursor to Interleukin-1-113 
1 MAEVPLASE MMAYYSGNED DLFFEADGPK QMIACSFGDLD CPLDGGIGL 
51 RISDHI-IYSKO FRGAASVVVA MDKLRKMLVP CPGTFGENDL STFFPFIFEE 
101 EPIFFDTWDN 
151 DMEGGVVFSMSFVGCEESND KIPVAL0USE KNLYLSCVLK DDIWTLGLES 
201 VDPKNYPKKK MERRFVFNRI EINNRLEFES AGFPNWYIST SQAENMPVFL 
251 CQTK000DIT DFTMQFVSS I 
il_I_n 
" 	 APVR SLNCTLRDSG GVSSLVMSOPY ELKALHLGQG 
151 DMEQGVVFSM SFVOOEESND K1PVALOLE KNLYLSCVLK DDKPTLQLES 
201 VDPKNYPKKK MEKRFVFNI'U EINNRLEFES AQFPNWVIST SGAENMPVFL 
251 CQTK000DIT DFTMGFVSS 
cleavage site 
101 EPIFFDTWDN EAYVHDPVR SLNCTLEDSQ OKSLVMSG 138 
Fig. 2.2 IL.1- Proteins and Initial Target 
Fmoc-amino acids were coupled in a stepwise manner to a peptide chain 
anchored to the solid support by the Wang linker136 (fig. 2.3). Electron 
donation from the p-oxygen enhances the acid-!ability of the peptide-resin 
link. Acid-labile side-chain protecting groups were based on the tert-butyl 
group, except in the case of arginine (Pmc, 58) 137 , histidine (trityl) 138 and 
cysteine (Acm,59) 139 . 	In this case the carboxamide side-chains of 
asparagine and glutamine were left unprotected. 	Use of the 
acetamidomethyl (Acm) group for cysteine protection allows the free thiol to 
remain masked during purification of the peptide, preventing oxidation and 
dimensation to cystine. Acm can be removed when desired by mercuric 
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Fig. 2.3 Cleavage of a Peptide From 
the Wang linker 
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Fig. 2.4 Activation of Fmoc- 
Amino Acids 
The peptide chain was elongated by one amino acid residue using an 
automated double-couple cycle. In most cases the first coupling used 
preformed symmetrical anhydrides (63) which were generated immediately 
before use by treating the Fmoc- amino acid (60) with 
diisopropylcarbodiimide, thus forming the symmetrical anhydride (63). The 
second coupling included 1-hydroxybenzotriazole (24) in the activation step 
thus forming the active HOBt ester (64). Knorr's reagent (65)140  and 
Castro's reagent (66) 141 are reported to form the HOBt ester (64) more 
rapidly, but are more expensive and difficult to prepare. Aminolysis of either 
activated derivative in fig. 2.4 forms the desired peptide bond. 
The use of two coupling methods has certain practical advantages which 
help drive reactions towards completion. In SPPS most peptide chains grow 
in cavities within the polymer matrix. Steric effects are enhanced under 
these conditions, so the highly activated symmetrical anhydride (63), which 
is rather bulky, may couple poorly compared to the less active but also less 
hindered HOBT-ester (64). 
Certain amino acid derivatives are not suited to this general procedure. 
Glycine is prone to diacylation and is generally only coupled once. For 
differing reasons the symmetrical anhydrides of asparagine, glutamine, 
arginine and histidine derivatives are not used. These amino acids are 
introduced by means of two couplings with the HOBt-ester. 
2.2.3 Monitoring of Chain Assembly 
It is very useful to have a measure of the incorporation of each successive 
amino-acid so that couplings which proceed slowly or incompletely may be 
identified and dealt with. If couplings do not proceed in a quantitative 
manner then deletion and termination side-products will be produced. 
These may differ in their physical properties only slightly from the desired 
peptide and be very difficult to remove from it following cleavage from the 
resin support. 
The goal of monitoring in SPPS is to achieve fully automated synthesis in 
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which the completeness of each coupling reaction is tracked and acylating 
conditions maintained until quantitative peptide bond formation is attained. 
Only then will the cycle proceed to the next amino acid. 
This goal has not yet been successfully attained despite several 
attempts142 . One major difficulty is the fact that the desired product is resin-
bound and thus difficult to characterise by spectroscopic means. This can 
be overcome if samples of the peptide-resin are removed and analysed in 
some way, but the additional time, manipulation and mechanical losses are 
undesirable and render the process less amenable to automation. Testing 
in this manner with ninhydrin is still a useful technique in manual and semi-
automated syntheses. 
Several methods measure the removal of activated amino acid from the 
reaction solution. This can be difficult to quantify in SPPS because reagents 
are generally applied in excess. Further, this technique does not give direct 
information about the efficiency of coupling. Decreases in concentration of 
the active species may be due to effects other than aminolysis, for example 
hydrolysis. 
Because of the difficulties in monitoring the coupling step we chose to 
concentrate on deprotection. When Fmoc-peptide-resin is treated with 
piperidine the N-terminus becomes exposed with the resulting production of 










Flg.2.5 Generation of the "Deprotection Chromophore" 
The resulting adduct (69) has a strong absorbance at 300nm, measurement 
of which allows calculation of the amount of Fmoc present and hence the 
degree of incorporation of the last amino acid. 
This measurement can be utilised as a monitoring tool in several 
conceivable ways. Firstly as a batchwise procedure, where the effluent 
from deprotection can simply be passed through a calorimeter on its way to 
waste. Secondly as a continuous flow set-Up where the deprotection 
solution is recirculated between the reaction vessel and colorimeter, giving 
time-dependent monitoring of the reaction. Thirdly as an analytical 
technique, whereby small amounts of peptide-resin can be removed, treated 
with piperidine,and the appropriate action taken depending on the amount of 
Fmoc present. 
We have developed a system combining the simplicity of the first method 
with some of the information content of the second. The peptide-resin batch 
is treated with four separate volumes of piperidine and the absorbance of 
the effluent from each treatment is determined. The quantity of reagent and 
time of reaction are chosen so that for most peptides deprotection will 
proceed almost quantitatively in the first run. Substantial quantities of 
chromophore in subsequent runs signify an unusually slow deprotection. 
Fig. 2.6 shows the application of this monitoring method to the assembly of 
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Deprotection following coupling of: 
Lys 132 	 G1n133 
Fig. 2.6 Successive Amino Acid Incorporation in the Solid-Phase 
Synthesis of IL-1-3-pre 102-138 
Fig. 2.6 illustrates several noteworthy features of this technique. The drop 
in incorporation is preceded by a rise in apparent incorporation to over 
100%. This drop is also preceded and accompanied by an increase in the 
relative absorbance of the second and third deprotection steps. The 
method appears to have unexpected predictive properties. Once 
deprotection has occurred it is too late to rectify a problem which happened 
at the previous coupling step, but if the next step can be predicted to be 
difficult then action can be taken to.improve incorporation, such as using a 
larger excess of acylating agent or allowing coupling to proceed for longer. 
2.2.4 Acidolysis of Protected Resin-Bound Peptides 
Use of base-labile Fmoc Naprotection means that the resin-peptide linker 
and all side-chain protecting groups may be chosen to be highly sensitive to 
acid. This permits relatively gentle cleavage conditions to be used. The 
general reagent in this case is 95% aqueous TFA, which contrasts with the 
final I-IF-based cleavage required for peptides assembled using Boc Na 
protection. This is advantageous in minimising certain side-reactions, e.g. 
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nucleophilic centres to generate undesired products, e.g. the irreversible 
alkylation of tryptophan by the tertiary butyl cation 143 . 
Fig. 2.8 Alkylation of Tryptophan 
Additional reagents are normally included in the cleavage mixture in order to 
minimise these side-reactions. Examples of auxilliary nucleophiles which 
scavenge these reactive species are shown in fig. 2.9. Suitable 
combinations of these (and many other) compounds are included, 
depending on the sequence of the particular peptide which has been 
assembled. 
OH 	Me 	 CH3 
I (75) 	S (76) 	
SH 	Me sflr C (77) 	(78) 
(79) 
	
L) 	 SH Me 	
H 
phenol 	thioanisole 	ethane-1,2- ethylmethyl- 3-methyl- 
dithiol 	sulphide 	indole 
Fig. 2.9 Useful Scavengers in Acidolytic Cleavage 
Another way of reducing the extent of these side-reactions is to carry out 
cleavage at reduced temperatures. However this also slows the desired 
reactions, so acidolysis is normally carried out at room temperature with a 
suitable scavenger mixture. Reference 144 gives a practical ly-oriented• 
review of cleavage procedures. 
IL-i --pre 102-138 contains several residues which are subject to this type 
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of side-reaction, especially tryptophan, tyrosine and methionine. Because 
of the protecting groups used, t-butyl cations will be generated on 
deprotection, along with the particularly troublesome trityl and Pmc cations 
from histidine and arginine respectively. A suitable scavenger mixture 
includes water, phenol, thioanisole, EDT, EMS and N-acetyltryptophan. 
The cleavage mixture for IL-1-0-pre 102-138 was analysed by HPLC at 
intervals. Little change in the trace was observed after 2.5 hours and this 
was taken to be the optimum deprotection time. The crude peptide is 
obtained by concentrating the deprotection mixture followed by trituration 
with diethyl ether. Subsequent dissolution of the material so obtained was, 
on occasion, troublesome. Attempts were made to extract the peptide from 
the cleavage mixture by treating the concentrate with water/diethyl ether 
mixtures and separating the phases. However IL-1-0-pre 102-138 has a 
rather low solubility in water, and increasing the water-soluble organic 
content of the mixture with methanol or acetonitrile led to inseparable 
mixtures. 
2.2.5 Purification of IL-1-3-pre 102-138 
The purification of peptides produced by stepwise solid-phase synthesis is 
in general a non-trivial problem. The crude peptide will be a mixture of the 
desired product and some combination of the following contaminants: 
solvents, scavengers, and reagents; 
terminated peptides; 
partially protected peptides; 
rearranged peptides; 
products of side-reactions. 
The first type of impurity is normally relatively easy to remove from the 
mixture, being rather different in character to the desired product, but those 
in types ii) to v) are rather more troublesome. The physicochemical 
properties of these impurities become relatively more similar to the correct 
product with increasing chain length, and in general longer peptides are 
more difficult to purify than shorter ones. 
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2.2.5a Gel Filtration, or Size-Exclusion Chromatography 
This simple group separation exploits differences in the size of components 
in a.mixture. It involves passing a solution through a bed of bead-formed 
polysaccharide gel. Molecules partition between the mobile phase (eluant) 
and the stationary liquid phase within the beads of the gel. The partition 
coefficient depends on the rate of access to the stationary phase via pores 
in the beads. Large molecules enter the beads less easily than small 
molecules and are thus eluted more quickly. Various gel-filtration media are 
commercially available, differing in their structure, degree of cross-linking 
and mechanical robustness. 
The resultsof Sephadex column chromatography on crude IL-1-0-pre 102-
138 are shown in fig. 2.10. 
2.2.5b Ion-Exchange Chromatography 
Peptides carry a nett charge at all values of pH other than at the iso-electric 
point (p1), which is a characteristic of each peptide. The counter-ion of the 
peptide can be immobilised on a solid-support which can then act as the 
stationary phase for this type of separation. Components of the mixture will 
then partition between the stationary and mobile phases to an extent 
depending on the relative strength of interaction with the solid support. 
Increasing the ionic strength of the eluant or bringing its pH closer to the p1 
of the desired peptide results in a reduction in the strength of this 
interaction. A gradient using either or both of these properties will thus 
result in elution of components in order of p1. 
Figs.2.1 la and b show the result of ion-exchange chromatography on the 
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Fig. 2.10 Gel Filtration Chromatography 
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Fig. 2.11a Anion-Exchange Chromatography on 
lL-1-3-pre 102-138 
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2.2.5c High Pressure Liquid Chromatography (HPLC) 
Reversed-phase HPLC depends in principle on the hydrophobic interaction 
of the components in a mixture with alkyl chains (normally C8 or C18) which 
are bound to the solid-phase. Application of a gradient of an organic solvent 
in the aqueous mobile-phase results in elution of peptides of increasingly 
hydrophobic character. The speed of this technique and the high degree of 
control over the separation makes this a particularly good tool for the 
demanding task of separating very similar molecules. 
The results of preparative HPLC on the major component after ion-
exchange chromatography is shown in fig.2.12. 
2.2.6 Analytical Techniques in Peptide Purification 
Analysis of the products of each stage of the protocol is crucial to the 
success of the purification. HPLC in analytical mode was the primary 
method for studying the products of each step in purification. Speed, 
resolution and low sample requirements make this especially convenient. 
Fig. 2.13 shows how the sample became increasingly pure after the 
application of each separation technique. Electrophoresis (iso-electric 
focussing) was applied at each stage, and an increasingly sharp band 
corresponding to a p1 of 4.3 was observed. 
Other analytical methods are essential for confirming the purity and more 
importantly the identity of the product. Amino acid analysis and mass 
spectrometry are particularly useful. Fig. 2.14 shows how the amino acid 
analysis of acid hydrolysates of the various samples gave results which 
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Fig. 2.12 Preparative Reversed-Phase HPLC 
on IL-i --pre 102-138 
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Fig. 2.14 Amino Acid Analysis of IL-1--pre 102-138 
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Fast atom bombardment mass spectrometry (FAB-MS) gave little evidence 
for the presence of the correct molecular ion until after the peptide had been 
purified by HPLC, but the peak resulting from the required molecular ion 
was then the strongest in the spectrum. 
2.2.7 Alternative Approaches to the Initial Target 
The purification of IL-1-0-pre 102-138 was a time-consuming and difficult 
task yielding only 3.8 milligrams of the desired product after HPLC, an 
apparent efficiency of approximately 0.2%. Though this could certainly be 
optimised, some thought was put in to methods of easing the difficulties 
which had been encountered. 
As the choice of the exact termini,," , of the target peptide was somewhat 
arbitrary it was assumed that slightly different peptides would have similar 
biological properties to IL-1-0-pre 102-138 whilst possibly allowing easier 
purification. 
IL-1-0-pre 98-138 differs from 101-138 only by extending the N-terminus of 
the original peptide by the sequence Phe-Glu-Glu-Glu. It was felt that 
introduction of this highly charged region would provide a useful "tag" for 
anion-exchange chromatography, emphasising the difference between 
prematurely terminated peptides and the desired product, and hence easing 
purification. Surprisingly however, this peptide had rather low solubility in 
aqueous solvent 'necessitating the use of denaturing agents and their 
subsequent removal. These complications made purification of this peptide 
even more difficult than lL-1-0-pre 102-138 and was abandoned at a 
relatively early stage. 
Attempts to purify IL-1-0-pre 102-138 with a free cysteine were equally 
problematical. Aggregation and the resulting insolubility proved 
unsurmounted problems. 
Removing the cysteine altogether and replacing it with alanine (Alal 24-IL-1- 
f3-pre 102-138) proved more practical. This change was felt to be 
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reasonable in light of the fact that IL-1-3-pre 102-138 showed biological 
activity whilst carrying the ACM group on the thiol side-chain of cysteine, 
implying that the free thiol was not essential. In this case synthesis 
proceeded rather better, and the crude peptide was purified in one step by 
carefully controlled reversed-phse HPLC. The resulting product gave a 
good analysis in comparison to that obtained by multi-step purification on IL-
1- t3-pre 102-138. 
Fig. 2.15 Analysis of Ala124-IL-1-3-pre 102-138 
2.2.8 Mapping the Cleavage Region of lL-1--pre 
In general, peptides of the size discussed in the last section are expensive 
and difficult to prepare. It was felt important to define more precisely those 
areas of the 37-peptide which were responsible for any biological activity. 
We set out to map this region of the precursor by preparing overlapping 
dodecapeptides as shown in fig. 2.16. This can be considered as analogous 
toepitope mapping of proteins. 
c1eavae site 
101 EPIFFDTWDN EAYVHD$APVR SLNCTLRDSQ GKSLVMSO 138 
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Fig. 2.16 Target Peptides From the Cleavage Region 
Fig. 2.17 shows the incorporation of each successive amino acid in the 
assembly of these six peptides as determined by the absorbance of the 













1 2 3 4 5 6 7 8 9 10 11 12 
Residue Number: 
Fig. 2.17 Chain Assembly of Dodecapeptides 
The synthesis of these peptides was generally satisfactory. A drop in 
incorporation of 2-15% was observed over the first three couplings in five 
cases, though lL-1-0-pre 117-128 suffered a 35% drop on one particularly 
hindered coupling. Four of the peptides gave essentially complete acylation 
throughout the remainder of their syntheses, but IL-1--pre 117-128 had 
one more poor coupling (5% drop) and lL-1-13-pre 127-138 had a run of 
several consecutive poor incorporations. All these peptides were purified in 
one step by reversed-phase HPLC, and all gave satisfactory amino acid 
analyses, FAB mass spectra, and analytical HPLC profiles. 
2.2.9 Synthesis of Peptide Amides 
IL-.1-0-pre 111-122 and 117-128 were also prepared as the C-terminal 
amide/ N-terminal acetyl derivatives. This gives a peptide which should 
more closely resemble the character of that segment of the protein which it 
is designed to model. 
The Wang linker is not suitable for the preparation of C-terminal amides. 
Peptide-resin linkages such as those shown in fig. 2.18 are required. 
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Fig. 2.18 Linkers for Preparing Peptide Amides 
Treatment with acid causes cleavage of the linker-nitrogen bond as 
indicated in fig. 2.18 to generate a resin-bound stabilised carbocation which 
is presumably scavenged in an identical manner to other cations produced 
in acidolysis. Assembly of peptides on resin linker 82 proceeded similarly to 
assembly on the Wang linker and no additional problems were encountered 
in the purification of the products thus obtained. 
2.2.10 Modifications to IL-1-f3-pre 111-122 
Other derivatives of IL-1 -13-pre  111-122 were prepared in order to assist 
determination of biological properties. The addition of an N-terminal 
aminouridecanoyl group was expected to enhance the interaction of 
peptide with any membrane-bound IL-1 -p-pre processing activity. 
Introduction of the fluorescent dansyl group 147 was designed to aid 
visualisation of the cell location of these peptide derivatives and any 
products thereof. 
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Cleavage of the appropriate peptide-resin derivative prepared as shown in 
fig. 2.20 gives either 11 -aminoundecanoyl-lL-1 -3-pre1 11-122-OH (84), N-
dansyl- 11- aminoundecanoyl- IL-1-0-pre 111-122-OH (85), or dansyl- IL-1 - 
3-pre1 11-122-OH (86). 
The products of step ii) (fig. 2.20) were investigated by analytical HPLC 
using diode-array detection (fig. 2.21). Information as to the nature of each 
component of the mixture was derived from the UV spectra thus obtained, 
and revealed that dansylation had not proceded to completion. This was in 
fact a practical advantage as it allowed the isolation of both compounds 84 
and 85 from one preparative HPLC treatment. 
There are in fact four major components in the mixture at the end of step ii), 
two pairs of peaks of equal intensity. A similar unexpected pattern was 
found in the synthesis of acetyl-IL-1-0-pre 111-122-NH2 and IL-1 -P-pre106- 
117. 
In the case of acetyl-IL-1-3-pre 111-122-NH2 the two products were 
separated by isocratib HPLC (fig 2.22). Amino-acid analyses of acid 
hydrolysates of these products indicated that the composition was identical, 
and FAB-MS of each sample confirmed this (fig 2.23). High field two-
dimensional NMR showed significant differences between the two 
components, as shown in fig 2.24. 
Conformational isomerism was suspected, for instance cis-trans forms of 
the peptide bond adjacent to proline. This initially seemed to fit with the 
NMR evidence. The most revealing evidence came from amino-acid 
analysis of an enzyme hydrolysate of the two products (fig 2.25). Histidine 
and the two adjacent amino acids valine and aspartic acid were present in 
rather lower amounts in one component than in the other. It would seem 
that the two peptidic products are epimerically related, differing only in the 
configuration of the histidine residue. A more thorough analysis of the NMR 
spectra revealed that this hypothesis fitted rather better than conformational 
isomerism. A similar analysis was performed on the two forms of synthetic 
IL- 1-3-pre 106-117 and identical conclusions were arrived at. 
(83) 
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Fig. 2.21 Diode-Array Detection of Dansylated 11_4-3-pre 111-122 
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Fig 2.22 Purification of Acetyl-I L-1 -3-pre 111-122-NH2 
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Fig. 2.25 Enzyme Digestion on AcetyI-11.4--pre 111-122-NH2 
Histidine is known to be particularly sensitive to racemisation. Urethane Na-
protecting groups normally ensure the chiral integrity of most amino acids 
under normal coupling conditions, but when Boc-L-histidine protected with 
a benzyl group on the N(t) position of the imidazole ring was activated using 
DCC, rapid racemisation occurred 148 . 
Jones et al investigated the mechanism of this troublesome side reaction 
and found that the it-nitrogen was capable of intramolecular proton 













Fig. 2.26 Racemisation of Activated Histidine Derivatives 
Even electron-withdrawing t-substituted protecting groups such as the 
phenacyl group did not entirely overcome this reaction. 
N(r)-protected histidi ne derivatives are, however, generally acceptable 
provided that rather gentler methods of activation are employed, such as the 
use of HOBt esters. For most of the histidine-containing peptides prepared 
in our laboratory the use of N('r)-trityl-protected histidine offered no 
problems. The reason for the racemisation which occurred in the above 
noted cases is not known. 
-J 
Better, though more expensive alternatives are now commercially available 
with protecting groups regiospecifically introduced at the it-position, such as 
the t-butoxymethyl denvative 150 (89, fig. 2.27). These have been shown to 
give racemisation-free coupling even when activated with DCC. Compound 







Fig. 2.27 Nit(tButoxymethyI)histidIne 
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2.3 Biological Activity of lL-1--pre Subpeptides 
Studies on the effect of these synthetic peptides on the processing of IL-1 --
pre were carried out by J. Eastgate and G. Duff of the Rheumatic Diseases 
Unit, Northern General Hospital, Edinburgh 151 . 
The main method for the detection and identification of IL-1 proteins was 
Western blotting following SDS-polyacrylamide gel electrophoresis. In this 
technique the components of a mixture are separated on the basis of 
molecular weight. The gel is then blotted onto a nitrocellulose membrane, 
transferring a portion of the separated materials. Treating this membrane 
with labelled antibodies allows visualisation of all components to which the 
antibody will bind. 
IL-1 -0-production was investigated in a series of cell lines. One particular 
monocytic line (THP-1) was shown to produce high levels of both 31 kDa IL-
1 -p-precursor and the active 17 kDa form when stimulated with PMA, and 
was used in further studies of the processing event. 
The cellular localisation of this proteolytic cleavage was determined by 
fractionating cell culture samples into supernatant, membrane and lysate. 
The ability of each fraction to cleave the lL-1-3-precursor was tested. 
Membrane preparations were found to liberate the largest amount of 17 kDa 
IL-1 -0. The addition of fresh THP-1 cells to a sample of the IL-1 -0-precursor
also resulted in the production of 17 kDa IL-1 -0. 
These studies were repeated in the presence of known protease inhibitors, 
and in the presence of several of the IL-1 -13-pre  subpeptides whose 
synthesis was described earlier. The senne protease inhibitors aprotinin 
and leupeptin decreased the amount of 17 kDa lL-1-13 produced from 
membrane preparations or fresh cell cultures as judged by Western blotting, 
as did synthetic IL-1 -3-pre 102-138 (see fig. 2.30). 
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A: membranes + IL-i -3-pre 
B : membranes + IL-i -3-pre + aprotinin 
C: membranes + IL-1-13-pre + IL-1-3-pre 102-138 
Fig. 2.30 Western Blot Showing Inhibition of IL-1-3-pre 
Processing 
Acetyl lL-1--pre 111-122-NH2 altered the time course of 17kDa IL-1-13 
production in the same cultures (data not shown), apparently showing 
partial inhibitory activity only during the early stages of the experiment (1-2 
hours). None of the other synthetic peptides showed inhibitory activity. 
Fig. 2.30 shows several low molecular weight bands in lane C that are 
detected by the IL-1 -3-pre antiserum. This suggests: i) that IL-1 -0-pre 102-
138 is recognised by antibodies to IL-1-0-pre; and ii) that the peptide is 
being broken down in some way during the experiment. More detailed 
investigation of the nature of these bands would be necessary in order to 
determine if this peptide is a substrate for specific lL-1-3-pre convertase 
enzymes. 
The time-dependent inhibition shown by Ac-lL-1-3-pre 111-122-NH2 
suggests that this peptide is being broken down to inert products. Black at 
a! 73  have shown that this peptide is indeed a substrate for their partially 
purified ICE activity, being cleaved between the same residues as IL-1-0- 
pre. The identity of the processing enzyme(s) in our experiments has not 
been determined. Characterisation of this activity would be extremely useful 
to establish if more than one specific IL-1 -3-pre converting enzyme exists. 
2.4 NMR Studies on IL-1-f3-pre Subpeptides 
A major goal of this project was to characterise the structure of the 
processing site of the precursor to IL-1-0, and a key hypothesis was that 
subpeptides from this region of the protein should closely mimic the native 
conformation of the processing site. Indirect evidence for the validity of this 
hypothesis came from studies on the intact protein. CD spectra indicate 
that the N-terminal third of IL-1-13-pre forms a separate domain to the C-
terminal two thirds46. The cleavage region thus appears to take the form of 
the link between the two domains and might be expected to have a distinct 
structure independent of that of the domains themselves. The noted 
susceptibility of this region to various proteolytic activities indicates a rather 
open structure for this part of the precursor. Finally the X-ray structure of 
active IL-1-P43 indicates that the N-terminal residues do not occupy well-
defined positions in the crystal lattice. 
X-ray diffraction crystal structure determination remains the most important 
method for determining the structure of proteins. This technique is not 
particularly well-suited to the study of peptides because in the solution 
phase many different conformational states may be populated. This makes 
crystallisation of peptides rather difficult and limits the practicality of this 
approach. Nuclear magnetic resonance (NMR) allows analysis of samples 
in the solution phase and is thus more practical and possibly more relevant 
than X-ray diffraction studies on peptides. It may be possible to identify 
several populated conformations and the dynamic relationship between 
them. 
The large number of protons in even relatively small peptides (around 100 
for a dodecapeptide) leads to very complicated NMR spectra. To assign the 
data thus obtained it is necessary to use two-dimensional techniques which 
both resolve the information and provide additional aids to its assignment. 
The general scheme for 2-D NMR spectroscopy is shown in fig. 2.31 along 
with examples of the sort of information obtained. Systematically varying 
one of the parameters of the pulse sequence, commonly the time between 
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two pulses, permits a set of free induction decays (FIDs) to be obtained. 
Two dimensional Fourier Transform converts this into a matrix m1(F1,F2 1), 
m being the magnitude of signal at any data point and Fx being the 
chemical shift in dimension x. 
Fig. 2.31 2-D NMR 
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2.4.1 Interpretation of 2-D NMR Spectra of IL-1--pre Subpeptides 
The procedure used here for the assignment of 2-D spectra has been 
tailored from the discussion of Wüthrich 152. All IL-1-3-pre subpeptides 
studied here have been treated in essentially the same manner, illustrated 
here using the spectra of IL-1 --pre 111-122. 
The COSY spectrum shown in fig. 2.32 was obtained in D20. Amide and 
other exchangeable protons do not give signals under these conditions. For 
a peptide of this size it is relatively straightforward to assign most of the 
signals for each amino acid. As an example, the assignment for proline is 
shown. Repeating this experiment in H20 allows assignment of the amide 
protons by correlation with the aCH signals. 
Another method leading to the same information requires the TOCSY 
spectrum. Each vertical line in the portion shown in fig. 2.33 joins all the 
signals of one spin system. The protons of each amino acid form one or 
more distinct spin system(s). Several amino acids can give the same spin 
system, for example Ser, Cys, Asp, Asn, His, Phe, Tyr, and Trp all show an 
AMX system. There are four examples of this class of amino acid in IL-1 -3-
pre 111-122 (marked with a U in fig 2.33) which cannot be unambiguously 
distinguished from the TOCSY (or COSY) data. A further complication is 
the presence of multiple copies of certain amino acids. The A3X patterns 
deriving from Ala 112 and 117, and the A3133MX systems of Val 114 and 
119 cannot be distinguished from this data alone. 
These problems can only be surmounted with any certainty with the aid of 
the through-space information obtained in the ROESY spectrum. Firstly 
certain spin systems of ambiguous origin can be assigned to specific amino 
acids. Observation of the ROESY cross-peaks indicated in fig. 2.34 allows 
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Fig. 2.32 Part of the COSY Spectrum of lL-1-3-pre 111-122 
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Fig. 2.33 Part of the TOCSY Spectrum of IL-1-3-pre 111-122 














A rather more powerful technique allows sequence specific assignment of 
all signals, dealing at a stroke with the problems outlined above. In 
general, a ROESY cross-peak is observed between an aCH proton and the 
aNH proton of the adjacent residue on the C-terminal side. Fig 2.35 shows 
how this relates to the COSYITOCSY through-bond interactions already 
obtained. 
4- - + COSY/TOCSY 
(_) ROESY 
R H%O 	R" H 0 H 




 H0 A" iO 
Fig 2.35 NMR Interactions in the peptide backbone 
Fig 2.36 shows the key part of the TOCSY/ROESY spectrum of IL-1-0-pre 
111-122. Related cross-peaks can be joined by horizontal or vertical lines 
as shown allowing sequential assignment, "walking the backbone" of the 
peptide. 
Once the full sequential assignment had been carried out, the remainder of 
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Fig. 2.36 "Walking the Backbone" of IL-1-[3-pre 111-122 
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space interactions. The only inter-residue cross-peaks were found to be 
due to protons on neighbouring amino acid residues. No indication of 
secondary structure was obtained. 
Spectra for IL-1 --pre 101-112 were not obtained due to the low solubility of 
the peptide, but an identical analysis was successfully performed on each of 
the remaining dodecapeptides. Full sequence specific assignment of each 
peptide was obtained, but in no case was evidence of secondary structure 
found. 
The available quantities of pure IL-1-0-pre 102-138 were too low to allow 
NMR spectra of this peptide to be obtained. However a sufficient amount of 
its analogue, Ala-124-IL-1--pre 102-138 was prepared , and COSY, 
TOCSY, and NOESY data sets were aquired from a solution of the peptide 
in 20% CD30H/ 80% H20. Identification of the spin systems is shown in fig 
2.37, and the results of correlating the TOCSY/NOESY i-i+1 data are shown 
in fig. 2.38. 
There are two main reasons why it is impossible to complete the sequence-
specific assignment of this peptide. Firstly several peaks lie under, and are 
obscured by, the water signal. Secondly, and more importantly, many of the 
NH or CH signals are degenerate causing ambiguity in identification of 
related cross-peaks. Uncertainty as to the origin of around half of the 
observed peaks makes searching for elements of secondary structure 
unproductive. In fact the high degree of degeneracy is an indicator of a 
random coil-type structure for the peptide. 
Observation of elements of secondary structure in this peptide would 
provide strong evidence for the conformation of this region of 
precursor. The indications from our studies are that the peptide takes up a 
more random structure. This is rather inconclusive : whilst it is possible that 
this accurately reflects the nature of the cleavage site it may be that the role 
of the domains in determining the structure of the inter-domain region has 
been underestimated. With improved knowledge of the structure of IL-1 -0  
and its precursor it should be possible to design better mimics of this region 
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Fig. 2.37 Part of the TOCSY Spectrum of Ala-124 IL-1-3-pre 102-138 
Showing Identification of the Spin Systems 
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Fig. 2.38 Partial Walk Along the the Backbone 
of Ala-124 IL-i --pre 102-138 
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2.5 Side-ChaIn-Protected Carboxamide Amino Acids 
2.5.1. Problems with Carboxamide-Containing Amino Acids 
The primary amide side-chains of asparagine and glutamine do not in 
general compete with the a-carboxyl group in activation and coupling steps 
of peptide synthesis. Hence they do not give rise to branched peptides and 
have most often been incorporated with a free carboxamide group. 
There are however several problems which are encountered when this 
strategy is employed. A number of troublesome side-reactions have been 
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Fig. 2.39 Side-reactions of Glutamine 
The main difference between these amino acids is the reluctance of 
asparagine to close the ring in which its own a-amino group participates (fig 
2.39ii). The lactam (95) produced when an N-terminal glutamine undergoes 
this side reaction may ring-open to give a glutamyl rather than glutaminyl 
derivative. Also, the acylated a-amine is a poor nucleophile and can cause 
chain termination. 
Imide formation (fig 2.391) offers the possibility of subsequent ring-opening 
to either the a- or co-peptide bond. Similar imide formation can occur even 
within peptide chains in the presence of base (93; X=NH-peptide). Ring-
opening of 94 has the nett effect of either hydrolysing the a-amide to an 
aspartyl/glutamyl peptide or cleaving the peptide bond. This is particularly 
troublesome in stepwise syntheses with Fmoc-amino acids where repetitive 
treatments with base are used to cleave each successive NO-protecting 
group. 
Dehydration of asparagine/glutamine (fig 2.39iii) results in the incorporation 
of 3-cyanoalanine or y-cyanobutyrine (97) respectively. This product can be 
the major component of the synthesis if free side-chain Gln/Asn derivatives 
are overactivated at the coupling stage. 
Side-reactions I) and iii) only occur to a significant extent during the 
activation of asparagine or glutamine, and parallels can be drawn between 
this side-reaction and the more general problem of racemisation (section 
1.2.3). The key intermediate is rather similar in each case. Appropriate 
choice of coupling conditions can reduce all these problems. In fact it is 
found that the activation conditions for asparagine and glutamine must be 
rather gentler than that necessary to minimise the racemisation of most 
amino acids. Treatment of Boc-asparagine with DIG gives 30-50% 
dehydration, but no detectable racemisation. Addition of HOBt was thought 
to eliminate this problem, but recent reports have cast doubt on this 
assumption. 
Peptide and amino acid derivatives with free carboxamide side-chains often 
have troublesome physical properties. They tend to have rather low 
solubility in the solvents used for peptide synthesis, an observation which 
has been attributed to their propensity towards intermolecular hydrogen-
bonding, leading to aggregation. 
The use of side-chain-protected asparagine and glutamine derivatives will 
disrupt these interactions and will also prevent the aforementioned side-
reactions. Amides are generally much more resistant to acidolysis than the 
corresponding esters. For instance NJ-tert-butyIasparagine is stable to 
TFA/anisole at room temperature whereas NP-tert-butylaspartate is rapidly 
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cleaved under the same conditions. It is necessary to use side-chain 
protecting-groups which will be easily cleaved on acidolytic deprotection. 
Several protected amide derivatives which have been used for this purpose 
are shown in fig. 2.40. The order of acid lability shown derives largely from 
the stability of the resulting carbocation. These have been derived 
experimentally for a series of the parent species as shown in fig 2.41. 
We reasoned that the dibenzosuberenyl group (104) might provide useful 
amide protection, and set out to prepare the appropriate amino acid 
derivatives. 
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Fig. 2.40 Asn/GIn Side-Chain Protecting Groups 
R-OH + H 	 R 	+ 	H20 
KR+ = 
	[R - OH] [H+] 
[R+] [H20] 
O(12)  CO 03 ) 	 (104) 
pKR+ = 4.75 
	





PKR+ 	- 133 
(106) 
pKR+ = -80 
CD (108) 
pKR+ = 140 
(105) 
KR+ = 
6 - 6 
Fig. 2.41 pK Values for Selected Carbocation 
157 
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2.5.2 Synthesis of Dibenzosuberenyl Derivatives 
Konig and Geiger154  prepared the dim ethoxybe nzhyd ryl- protected 
derivatives of asparagine and glutamine by treatment with 
dimethoxybenzhydrol in glacial acetic acid with a catalytic amount of conc. 
sulphuric acid. We applied the same procedure to the preparation of Fmoc-
Gln/Asn-(Dbse)-OH (109/110) and found that the work-up was eased by the 
precipitation of the desired product from the reaction mixture following 
overnight stirring. Compounds of this type were found to have a rather low 
solubility in all solvents, only dissolving appreciably in highly polar solvents 
such as DMSO or DMF. 
The dihydro-derivatives (Fmoc-Gln/Asn-(Dbsa)-OH, 111/112) and Bnpeoc-
denvatives155 (113/114) were also prepared by the same general method. 
2.5.3 Synthesis of Trityl Derivatives 
Sieber and Riniker 156 attempted to prepare Fmoc-Gln/Asn-(Trt)-OH 
derivatives by an analogous procedure to that described above, but 
obtained the desired product in only low yield after a laborious work-up. 
They found better results by side-chain tritylation of Z-Gln/Asn-OH, then 
removing the Z group by hydrogenolysis and reprotecting with Fmoc. We 
repeated their preparation of Fmoc-Asn-(Trt)-OH and obtained identical 
results. These compounds are now commercially available. 
2.5.4. Properties of Side-Chain-Protected Asn/GIn Derivatives 
The acidolytic cleavage of each amide protecting group was studied by 
time-dependent TLC or HPLC, and the results are shown in fig 2.43. The 
dibenzosuberenyl group showed a similar degree of acid-lability to the trityl 
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Bnpeoc Dbse 1 (113) 
Bnpeoc Dbse 2 (114) 
Fig 2.42 Dlbenzosu berenyl-type Asn/G In Derivatives 
Protection t½ % Deprotection 
Group (mins.) (t= 10 mins.) 
Dbsa (112) 10-15 60 
Mbh (100) 5-10 90 
Trt (101) <5 100 
Dbse (110) <5 100 
Fig. 2.43 Acidolysls of Glutamine Derivatives 
Acidolytic cleavage would be expected to be prolonged, and the differences 
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in deprotection times magnified, when these compounds are applied to 
SPPS, as stenc effects due to the polymeric support and the other residues 
of the peptide would hinder the reaction. 
Solubility is another key property which must be considered. It is important 
that the amino acid derivative should dissolve readily in suitable solvents. In 
automated SPPS an insoluble reagent could cause blockages in filters or 
piping with disastrous effects on the synthesis in progress. 
The solubilities of the relevant derivatives in two common solvents which are 
used for peptide synthesis are shown in fig. 2.44. 
Solubility (gImI) in: 
Protected 
Derivative 	 DMF 	DMF/dioxan (1:1) 
Fmoc-Asn-(Trt)-OH >0.2 >0.2 
Fmoc-Gln-(Trt)-OH >0.2 >0.2 
Fmoc-Asn-(Dbse)-OH 0.08 insol. 
Fmoc-Gin-(Dbse)-OH 0.2 0.05 
Bnpeoc-Asn-(Dbse)-OH >0.2 >0.2 
Bnpeoc-GIn-(Dbse)-OH >0.2 >0.2 
Fig. 2.44 Solubility of Protected Asn/GIn Derivatives 
The minimum solubility for a suitable reagent for SPPS is around 0.075 
g/ml. Fmoc-Asn-(Dbse)-OH in DMF barely meets this criterion, and must be 
used with great care in an automated system. Fmoc-Gln-(Dbse)-OH proved 
to be much better, though the rate of dissolution was rather slow and the 
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resulting solution was rather viscous, causing some difficulty in transfer 
steps. 
Bnpeoc/Dbse and Fmoc/Trt derivatives posed no solubility problems in 
either of the solvents tried, and would, at least in this respect offer suitable 
protecting group combinations for Asn/Gln. 
2.5.5 Application of Dbse Derivatives to Peptide Synthesis 
One side-reaction which has been noted in the use of side-chain-protected 
asparagine and glutamine arises from the stable cation which is produced 
on acidolysis. As discussed in section 2.2.4 , this can result in alkylation of 
sensitive amino acid residues. The indole ring of tryptophan has been 
noted as being particularly sensitive to this modification. 
Sieber and Riniker 158 prepared the decapeptide shown in fig. 2.45 and 
showed that alkylation of tryptophan occurred in case ii) (82%) whereas the 
correct product was obtained in 92% analytical yield in case i). 
Fmoc-Lys-Gl n(R)-His-Asn(R)-Pro-Lys-Tyr-Gln (R)-Trp-Asn(R)-O A 
R=(i) trityl or R=(ii) 2,4,6-trimethoxybenzyl 
Fig. 2.45 
The hexapeptide Phe-Pro-Asn-Trp-Tyr-Leu comprises residues 233-238 of 
the precursor to lL-1-0. As well as having potential IL-1 activity this is a 
useful test peptide for the new protecting group. 
Assembly of the tripeptide Trp-Tyr-Leu-O R proceeded as normal. 
Activation of Fmoc-Asn-(Dbse)-OH was achieved by adding the solid amino 
acid derivative in small portions to a stirred solution of DIC and HOBt in 
DMF. Thus activation and dissolution were combined in one step. The 
solution thus obtained can simply be taken up by the peptide synthesiser 
and chain assembly continued as normal. 
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This procedure overcomes the problem of the low solubility of Fmoc-Asn-
(Dbse)-OH in DMF. Though it requires the presence of the operator (hence 
not automated) it is not necessary to disrupt the coupling cycle. Asn-(Dbse) 
was successfully incorporated as determined at the subsequent 
deprotection step. The remaining residues were coupled without further 
difficulty. 
Acidolytic cleavage of the assembled peptide-resin gave a crude product 
which was purified by semi-preparative HPLC to give pure peptide in 39% 
overall yield from the initial coupling. The predicted amino-acid analysis and 
molecular ion (FAB-MS) were obtained. 
2.5.6 Comparative Studies on Asn/GIn Protection 
Four other peptides have been used to study the effect of altering the 
carboxamide protection on the chain-assembly process. These test 
peptides were chosen because of known difficulties in their preparation. 
Substance P is an undecapeptide amide which is involved in the 
transmission of the sensation of pain from sensory neurons. This had 
previously been prepared in this laboratory 146 and was known to be a 
difficult synthesis, having several successive poor couplings. Fig 2.46 
allows comparison of the effect of different amide protecting groups on the 
synthesis of this peptide. 
All the protected. glutamine derivatives show the same type of behaviour, 
dropping at the same point in each case. Coupling of the first glutamine 
residue results in a large drop and incorporation falls even further on the 
second glutamine. After this point all remaining couplings were more 
successful. The differences between the behaviour of Fmoc-Gln-(Trt)-OH 
and the corresponding Dbse, Dbsa, and Mbh derivatives are quantitative 
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Fig 2.46 Assembly of Substance P 
The peptide containing two unprotected glutamine side-chains behaved 
rather differently. Coupling of the first glutamine proceeded in quantitative 
yield, and the second also coupled relatively well compared to protected 
derivatives. However from this point onwards, several couplings did not go 
to completion. Incorporation of the N-terminal arginine(Pmc), essentially 
quantitative in all glutamine-protected syntheses, proceeded to less than 
40% in the glutamine-unprotected case. 
Kent159 has discussed the phenomenon of difficult sequences in peptide 
synthesis and has attributed this to aggregation of protected peptide chains. 
Evidence supporting this hypothesis has been found in NMR studies of 
peptide-resins from known difficult sequences, revealing a marked decrease 
in the mobility of the polystyrene backbone compared to the resins of known 
facile peptides. Further, FTIR studies of the same resins has indicated the 
presence of n-sheet-type hydrogen bonding160. 
Milton et a!160 have applied Chou and Fasman 161 conformational 
parameters to predict the structure of resin-bound peptides and have found 
positive correlation between the predicted degree of 13-sheet formation and 
incomplete acylation. They found that where the cumulative average P c* 
was lowest (corresponding to the greatest likelihood of 13-sheet formation) 
couplings were most likely to fail. 
Using their parameters, the prediction for the assembly of substance P is 
shown in fig 2.47. The prediction appears good in the case of assembly 
using unprotected glutamine, at least for the first eight or nine residues, only 
breaking down where the first side-chain-protected amino acids are 
incorporated. This might be expected since the Chou and Fasman 
parameters are derived from the structures of proteins which do not carry 
these groups. However, an even better correlation is found between the 
predicted degree of 13-sheet formation and incorporation in the glutamine-
protected cases. The reason for this is unclear. 
72- 
note: Low Pc*=  high predicted likelihood of 13-sheet formation 
Fig. 2.47 Substance P: 13-sheet Prediction 
Ell 
In the case of IL-1-3-pre 102-138 (fig. 2.48) less pronounced effects are 
predicted, but the region where incorporation begins to fall (see fig. 2.6) 
does indeed correlate with the most strongly favoured 3-sheet region. 
ibMVL5P1(JQSDKLLUNLSKVPADHVYALNOWTDFF I1' 
Fig 2.48 IL-11-f3-pre 102-138 ; -sheet Prediction 
Of rather more direct interest here is the difference between the glutamine 
derivatives. Why is trityl so much better than all the others? The answer 
could lie in the peptide-polymer rather than peptide-peptide interaction (as in 
the p-sheet interactions described above). 
The planar aromatic rings of the various protecting groups would be 
expected to interact with the phenyl groups of the polystyrene matrix via 
Van der Waals stacking forces. Tntyl's bulkiness discourages stacking 
interactions. Dibenzosuberenyl is rigid and almost planar, hence imposing 
strict demands on the orientation of stacking phenyl groups. 
Dibenzosuberyl is more flexible, and dimethoxybenzhydryl even more so, 
able to interact with phenyl groups at many orientations. 
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Thus incorporation correlates in a negative manner with ability to participate 
in stacking arrangements with the polymer. Such interaction would hinder 
coupling in two ways. Firstly an activated protected amino acid would 
diffuse less freely within the gel bead, and secondly a peptide carrying such 
a. protected residue would effectively introduce additional non-covalent 
cross-links to the matrix, reducing gel permeability. 
The behaviour in the case of IL-1-0-pre 101-112 was rather different. Fig 
2.49 shows that incorporation of Fmoc-Asn-(Trt)-OH was very poor indeed, 
whereas all other asparagine derivatives gave near quantitative acylation. 
The same pattern is observed again when the the corresponding glutamine 
derivatives are used in the assembly of IL-1 -P-pre 121-132 (fig 2.50). 
Coupling 
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Fig. 2.50 IL-11-f3-pre 121-132 : Incorporation 
The common factor in these two cases is the presence of the side-chain-
carboxamide derivative as the third residue to be coupled to the resin-linker. 
This position is particularly troublesome in peptide chemistry because the 
resin-dipeptide is uniquely well set up for intramolecular cyclisation 162 . 
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Fig 2.51 Diketopiperazlne Formation 
The dipeptide is lost from the resin and chain termination occurs. Evidence 
for this mechanism operating in the cases of the IL-1-3-pre subpeptides 
mentioned above was obtained from amino acid analysis of an acid 
hydrolysate of the resin-bound product. If simple capping had occurred 
after the poor incorporation of the tntyl-protected amino acid then a large 
amount of the first two amino acids should be detected. If, however, 
diketopiperazine (DKP) formation had occurred, then these amino acids 
should be present in approximately the correct proportion, as was indeed 
found. 
In fact the product obtained on acidolytic cleavage of 1 09-Gln-(Trt)-IL-1 -f3-
pre 101-112 was of superior quality to that derived from the other four 
preparations, though the yield was greatly reduced. 
Why does the coupling of trityl derivatives encourage DKP formation? The 
steric bulk of this group would again seem to offer an explanation. The - 
reactive carboxyl group of Fmoc-Gln-(Trt)-OH may be sterically hindered, 
thus lowering the rate of activation and, especially, coupling. If the rate of 
coupling is lowered and the rate of DKP formation remains constant (all 
other conditions being equal) then more of the side-reaction will take place. 
The rate of cyclisation to the diketopiperazine depends on the particular 
dipeptide involved 1 . The necessary formation of a cis peptide bond is 
greatly affected by the steric and chiral features of the constituent amino 
acids. Proline- and glycine-containing peptides are particularly disposed 
towards this side-reaction. The dipeptide IL-1 -p-pre 111-112, H-Glu-(O-
tBu)..AIa..O A would not be expected to be particularly sensitive to DKP 
formation. Indeed with any glutamine protecting group other than tntyl this 
is the case, and acylation proceeds much more quickly. IL-1 -3-pre 131-132, 
H-Gln-(PG)-Lys-(Boc)-O A is even more sterically hindered, hence even 
less DKP would be expected even allowing for a slow acylation. This is in 
fact what is observed. 
Modifications to the coupling strategy could lessen this problem. Use of a 
faster or less hindered activating agent should accelerate coupling and thus 
reduce the relative amount of DKP formation. 
We applied Knorr's reagent 140 to the activation of Fmoc-Asn-(Trt)-OH in the 
synthesis of IL-1-f3-pre 101-112. This reagent is reported to accelerate 
production of the HOBt ester. We found that the level of asparagine 
incorporation was raised to 60%, still considerably poorer than when any of 
the other derivatives when used with standard coupling methods. 
As has already been noted, this side-reaction has no damaging effect on the 
quality of the final peptide, indeed it may even give better results. 
Nevertheless it may result in a large decrease in yield and should be borne 
in mind. 
The conclusion of this section must be that trityl side-chain-protected 
carboxamide derivatives are the most suitable reagents developed to date 
for the incorporation of asparagine and glutamine in SPPS, except possibly 
when these residues occur as the third residue from the C-terminus of the 
desired peptide. They gain over unprotected derivatives in terms of 
solubility, prevention of side-reactions and prevention of inter-chain 
aggregation. They are however more expensive and difficult to produce, 
and may be slower acylating agents. 
Many improvements on the dibenzosuberenyl-type protecting group can be 
envisaged. Removing one or both benzyl groups would result in enhanced 
acid-lability whilst reducing the bulk of the side-chain (e.g. 119, and see fig. 
2.41). Brief attempts by us to prepare N(°-cycloheptatnene derivatives met 
with no success. The precise degree of acid sensitivity could be tailored by 
the introduction of substituents. Bulky substituents such as t-butyl on the 





Fig.2.52 Other Dibenzosuberenyl-Type Protecting Groups 
PP 
2.6 Concluding Remarks 
The results presented in this thesis offer some encouragement in the search 
for ICE inhibitors, though the goal is clearly still some way off. 
Biological testing in this system has proved to be an extremely demanding 
task, and the results have often been difficult to interpret. The current 
literature holds much promise of a clearer understanding of the mysteries 
which presently envelop interleukiri-1, and it is to be hoped that this will 
guide and simplify future work in this area. The ever-growing evidence of 
the role of IL-1 in disease states and the intellectual challenge of unravelling 
its role in homeostasis make this a field of great interest and potential. The 
excitement currently surrounding cyclosponn and related 
immunosuppressants offer a tantalising parallel to the IL-1 story. 
Structural studies of the subpeptides prepared in this study have shown 
that, in solution at least, they exist largely in random-coil-type 
conformations. Small linear peptides such as those described herein are 
unlikely to adopt a defined shape, since solvation and inter-molecular 
aggregation serve to disrupt all but the strongest elements of intramolecular 
structure. In this respect the results of NMR analysis of these 
dodecapeptides are to be expected. 
The results of structural studies on the larger peptide, ala-124-lL-1--pre 
102-138 are rather more disappointing. It had been hoped that a self-
contained subdomain might be present within these residues which could 
adopt a definite structure even in the absence of the large N- and C-terminii 
of IL-1--pre. This would appear not to be the case. 
Molecular modelling studies of 11-1 -0 have been initiated in this department 
and clearer insights into the next generation of peptides to be studied are 
already being obtained. 
n. 
Studies on protected side-chain carboxamide groups have, it is hoped, 
made a small but useful contribution to the developing methodology of solid-
phase peptide synthesis. The novel dibenzosuberenyl-type protecting 
groups described offer considerable potential, although trityl derivatives 
remain the most suitable thus far reported. The electronic properties of the 
dibenzosuberenyl group which make it a useful protecting group also invite 
applications in general synthetic organic chemistry. The first stages of 
investigations in this area are presently being undertaken, and initial results 
have been extremely promising. 
SPPS has reached a stage of maturity such that peptides can be rapidly and 
successfully prepared by non-specialists, resulting in a great multiplication 
of the applications of these compounds. The lingering presence of nagging 
problems such as the incorporation of Asn/Gln residues and the constant 
challenge of producing bigger and better molecules ensure that the role of 
the peptide chemist is far from obsolete. 
Chapter 3 Experimental 
3.1 Notes 
Melting points were taken in open capillaries on a BOchi 510 melting point 
apparatus and are uncorrected. Thin layer chromatography (TLC) was 
carried out using plastic sheets precoated with silica gel 60GF-254 (Merck 
5735) in the following solvent systems: A) chloroform/methanol/acetic acid 
(9:1:0.5); B) butanol/acetic acid/water (3:1:1); C) cyclohexane/diethyl ether 
(1:1). Visualisation of the components was achieved by a suitable 
combination of the following methods: UV absorption at 254 nm; acidic 
potassium permanganate; ninhydrin for compounds with free amino groups; 
Mary's reagent (4,4'-bis(di methylamino)diphenylcarbi nol) for acid functions. 
Optical rotations were measured on an AA1 000 polarimeter (Optical Activity 
Ltd.) using a 10 cm cell in the solvent indicated. Mass spectra were 
recorded on a Kratos MS50TC machine. Ultra-violet spectra were recorded 
on a Cary 210 spectrophotometer. Infra-red spectra were recorded on a 
Perkin-Elmer 781 spectrophotometer in the solution indicated or as a KBr 
disc. 1 H NMR spectra were recorded on either Bruker WP80 (80 MHz), 
WP200 (200 MHz), WH360 (360 MHz), or Varian VXR5000 (600 MHz) 
machines in the solvent indicated using tetramethylsi lane (TMS) as external 
standard (5H=0 . 00). 1 C NMR spectra were recorded on a Bruker WP200 
machine operating at 50.1 MHz in the solvent indicated using 
tetramethylsi lane as external .standard (c=°.°°).  All solvents were distilled 
before use, and the following were dried using the reagents given in 
parentheses when required: diethyl ether (sodium wire); dichioromethane 
(calcium hydride); tetrahydrofuran (sodium); methanol (magnesium-iodine). 
Dimethylformamide, 1 .4-dioxan and piperidine were Peptide Synthesis 
grade supplied by Rathburn Chemicals, Walkerburn, Scotland. High 
performance liquid chromatography was carried out using an Applied 
Biosystems system comprising 2x1406A solvent delivery system, a 1480A 
injector/mixer, and a 1783A detector/controller. Analytical columns were 
Applied Biosystems Aquapore RP300 018 reversed-phase silica (300A pore 
size, 7p.m spherical silica, 4.6mm internal diameter). Columns were eluted 
with a gradient of acetonitrile (far UV grade: Rathburn Chemicals) in water, 
with 0.1% TFA (far UV grade: Applied Biosystems) in both solvents, at a 
flow rate of 1 cm3/minute. Some combinations of column length and 
gradient are shown below, others are specified in the text. 
Column 	Gradient; 
Length (time In mins., %acetonitrile) 
A 	22 cm (0, 10),(30, 90),(31, 10) 
B 11 cm (0,10),(25,90),(26,10) 
C 	11 cm (0, 10), (30, 90), (3 1, 10) 
D 11 cm (0,15), (15, 30), (16,15) 
E 	11 cm (0,14),(20,14) 
The eluant was monitored at 226 nm unless otherwise noted. Preparative 
HPLC was carried out on the same equipment using columns of 9.2mm 
internal diameter unless otherwise noted. The conditions used are specified 
in the text. Simultaneous multiple wavelength detection was carried out 
using a LKB Pharmacia Diode-Array Detector and data processor. Amino 
acid analyses were carried out using an LKB 4150 alpha amino acid 
analyser on a hydrolysate obtained by one of the methods described in 
section 3.2.9. Peptide titration curves and iso-electric-focussing were 
carried out using LKB Pharmacia PhastGel electrophoresis equipment and 
developed using silver staining. Sequencing of peptides was carried out on 
an Applied Biosystems 477A sequencer at the WellMet sequencing facility, 
University of Edinburgh. 
3.2 Solid-Phase Peptide Synthesis 
3.2.1 Preparation of Fmoc-Amino Acid Resins 
A solution of Fmoc-amino acid (9.5 mmol, NovaBiochem or Raylo 
Chemicals unless otherwise noted) and N,N'-diisopropylcarbodiimide (DIG; 
0.744 cm3; 4.75 mmol) in dimethylformamide (DMF; 30 cm 3) was allowed to 
stand for 15 minutes prior to addition to a mixture of p-alkoxybenzyl alcohol 
polystyrene resin (crosslinked with 2% divinylbenzene)(0.79 mmol g -1 w.r.t. 
hydroxyl group; 2.0 g, 1.58 mmol) and 4-(N,N-dimethylamino)-pyridine 
(DMAP; Aldrich Chemicals; 30 mg) in DMF (15 cm 3). The mixture was 
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sonicated for 2 h then filtered and the resin washed thoroughly with DMF 
then diethyl ether. Drying in vacuo yielded Fmoc-amino acid-resin as off-
white granules. 
The loading of the Fmoc-amino acid-resin was determined by treating a 
weighed sample (2-4 mg) with piperidine (2.0 cm 3) and DMF (8.0 cm3). 
After sonicating for 20 minutes the UV absorbance of the supernatant was 
measured at 300 nm and the loading calculated using the Lambert Beer 
law. A typical preparation gave 75% coupling for a loading of Ca. 0.6 mmol 
g 1 . 
3.2.2 Capping of Unreacted Resin Sites 
Fmoc-peptide-resin (0.5 mmol) was treated with acetic anhydride (0.10 g, 
1.0 mmol) and pyridine (0.080 g, 1.0 mmol) in DMF (7 cm 3). The mixture 
was shaken for 2.5 minutes then filtered and treated with a further identical 
portion of acetic anhydride and pyridine in DMF. After shaking for a further 
3.5 minutes the mixture was filtered and the resin washed thoroughly with 
DMF. 
3.2.3 Removal of Fmoc Group 
Fmoc-peptide-resin (0.5 mmol) was treated with four portions of 20% 
piperidine in DMF (9.0 cm 3) and shaken for 5, 3, 3, and 1 minute 
respectively. The mixture was filtered prior to each addition and the UV 
absorbance of the filtrate measured at 300 nm on each occasion. After the 
last treatment the peptide-resin was washed thoroughly with DMF. 
3.2.4 Activation of Fmoc-Amino Acid 
i) Fmoc-amino acid (1.0 mmol) was dissolved in DMF (8.0 cm 3) and treated 
with 0.5 M DIC in DMF (2.0 cm 3; 1.0 mmol). The solution was allowed to 
stand for 15 minutes. 
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ii) Fmoc-amino acid (1.0 mmol) was dissolved in DMF (4.0 cm 3) and treated 
with 0.5 M DIG in DMF (2.0 cm 3; 1.0 mmol) and 0.5 M 1-
hydroxybenzotriazole (HOBt; Fluka) in DMF (2.0 cm 3 ; 1.0 mmol). The 
solution was allowed to stand for 15 minutes. 
Initially most Fmoc-amino acids were coupled using procedure I), then 
recoupled using procedure ii). The following were coupled using procedure 
ii) twice: Arg, GIn, Asn, His. 
3.2.5 Coupling of Activated Amino Acid to Peptide-Resin 
Activated amino acid solution (from 3.2.4 i or ii) was added to peptide-resin 
(0.5 mmol). The mixture was shaken for 30 minutes then filtered and the 
resin washed thoroughly with DMF. 
3.2.6 Automated Chain Assembly 
All peptides were assembled using an Applied Biosystems 430A peptide 
synthesiser. The initial resin for the synthesis of peptides with free C-
terminii was that described in step 3.2.1. If a C-terminal amide was desired 
then 5-(Fmoc-amino)-dibenzosuberyl-2-r6sin was used. Syntheses were 
normally carried out on an initial scale of 0.5 mmol. Steps 3.2.2 to 3.2.5 
inclusive ("capping", "deprotection", "activation"(i and/or ii), and "coupling") 
comprise the coupling cycle used to elongate the resin-bound peptide by 
one residue. The timing and logistics of the coupling cycle are shown in fig. 
3.1. 
Once all amino acids have been coupled, one further round of capping and 
deprotection (steps 3.2.1 and 3.2.2) gives the free N-terminus. If desired 
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3.2.7 Fmoc-Amino Acids 
The following Fmoc-amino acids were always incorporated with no further 
protection: 
Glycine; Alanine; Valine; Leucine; Isoleucine; Phenylalanine; Tryptophan; 
Proline; Methionine. 
The following were always incorporated with the side-chain protection 
shown: 
Glutamic acid; Aspartic acid; Tyrosine; Serine; Threonine: (OtBu), 
Arginine: (pentamethylchromansulphonyl; Pmc 137), Lysine (Boc). 
The particular derivative used to incorporate the following amino acids will 
be specified for each peptide. 
Glutamine; Asparagine; Histidine; Cysteine. 
3.2.8 Acidolytic Deprotection 
Peptide-resin (0.5 g) was treated with 95% aqueous TFA (10 cm 3 ) 
containing an appropriate scavenger mixture (specified in the text). Aliquots 
of the mixture were analysed at regular intervals by HPLC and the optimal 
cleavage time determined (1-4 h). The mixture was filtered and the filtrate 
concentrated in vacuo to Ca. 1 cm3 of oily liquid. Addition of ice-cold diethyl 
ether (20 cm3) gave the peptide as a white to off-white solid (0.1-0.4 g). 
3.2.9 Hydrolysis of Peptides for Amino Acid Analysis 
i) Acid hydrolysis: Peptide (1-3 mg) was treated with 3 M aqueous p-
toluenesulphonic acid (pTSA; 1.0 cm3) and placed in a sealed, evacuated 
Carius tube. For peptides containing tryptophan a tryptam i ne-satu rated 
pTSA solution was used. After heating to 110°C for 18-36h the hydrolysate 
was treated with 1 M sodium hydroxide (2.0 cm 3) and water (2.0 cm3). 
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ii) Proteolytic digestion: Peptide (2-3 m g) was treated with 5% formic acid 
(0.25 cm3) in an Eppendorf tube and pepsin in 5% formic acid (Sigma)(20 
p1; 1 mg/ cm3) added. The tube was incubated at 40°C for 24 h, then 
lyophilised. 0.2 M Ammonium hydrogen carbonate solution (0.25 cm 3) was 
added to the residue, and the pH adjusted to 7.75 ±0.25 with dilute 
ammonia or acetic acid. 0.025 M Manganese chloride (50 p.1) and leucine 
aminopeptidase M (Sigma)(40 U/cm3 ; 15 p.1) were added, and the tubes 
incubated at 40°C for a further 48 h. The samples were repeatedly 
lyophilised to remove salt, then taken up in citrate buffer (pH 2.2; 2.0 cm 3 ). 
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3.3 Experimental 
lnterleukin-1 -3-Precursor 102-138 (120) 
H-Pro-I Ie-Phe-Phe-Asp-Thr-Trp-Asp-Asn-G lu-Ala-Tyr-VaI-His-Asp-Ala-Pro-
Val-Arg-Ser-Leu-Asn-Cys-Th r-Leu-Arg-Asp-Ser-G ln-G ln-Lys-Ser-Leu-Val-
Met-Ser-Gly-OH 
The initial resin was Fmoc-GIy.®(0.6 mmol g -1 ; 0.85 g, 0.5 mmol). The 
side-chain amide groups of asparagine and glutamine were left unprotected. 
Histidine was protected with a trityl group on the 'c-nitrogen of the imidazole 
ring (His-(Trt)). The thiol group of cysteine was protected by an 
acetamidomethyl group (Cys-(Acm)). Approximately one third of the 
peptide-resin was removed after 21 couplings because of excessive 
swelling of the peptide-resin. The weight of peptide-resin after chain 
assembly was 2.05g. Resin-bound-peptide (0.4 g) was cleaved for 2 h with 
a solution of 2.5% thioanisole, 2.5% anisole, 2.5% ethylmethylsulphide 
(EMS), 2.5% N-acetyltryptophan, and 5% water in TFA (10 cm 3), giving a 
mixture of crude peptide and scavengers (0.75 g). This mixture was 
dissolved in the minimum volume of 30% aqueous acetic acid and passed 
down a column of G-25 Sephadex (2.5x150 cm) eluted with 30% aqueous 
acetic acid at 25 cm 3/hour. UV absorbance of the eluant was monitored at 
254 and 277 rim. Appropriate fractions were combined and lyophilised to 
yield crude peptide (0.19 g). A portion (0.10 g) was dissolved in the 
minimum volume of 0.05 M aqueous ammonium hydrogen carbonate 
solution and the pH adjusted to 8.0 with 0.2M aqueous ammonia. The 
resulting solution was passed down a DEAE-cellulose column (1.5x30 cm) 
and eluted with 0.05 M aqueous ammonium hydrogen carbonate solution 
(pH 8.0). The UV absorbance of the eluant was monitored at 254 and 277 
nm. After a small amount of unbound material was eluted a linear gradient 
of increasing concentration of ammonium hydrogen carbonate was applied 
to a final concentration of 0.3M. The total volume of the eluant was 600 cm 3 
and the pH was maintained at 8.0 throughout. Appropriate fractions were 
combined and lyophilised. Those fractions corresponding to the main 
absorbance peak showed the cleanest analytical HPLC trace and amino 
acid analyses closest to the desired values. A portion of the major product 
was dissolved in the minimum volume of 0.025 M aqueous ammonium 
acetate solution and the pH adjusted to 3.5 with 0.1 M aqueous acetic acid. 
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This solution was passed down a column of CM-Sephadex (1x20 cm) and 
eluted with 0.025 M aqueous ammonium acetate solution (pH 3.5) at 15 
cm3/hour. The UV absorbance of the eluant was monitored at 254 and 277 
nm. After a small amount of unbound material had been washed off a linear 
gradient of increasing ammonium acetate concentration was applied, the 
final concentration being 0.3 M. The total volume of the eluant was 600 cm 3 
and the pH at the end of the procedure was 4.5. Appropriate fractions were 
combined and lyophilised. The remainder of the major product from DEAE 
column chromatography was dissolved in the minimum amount of 20% 
aqueous acetonitrile and purified in six portions by preparative HPLC (22 cm 
column; flow 3.5 cm 3/minute; isocratic 29% acetonitrile). Lyophilisation of 
the appropriate fractions yielded the title compound (3.8 mg). 
FAB-MS m/z 4313.0, C1H287N65075S2 requires 4312.9; Analytical HPLC 
(22 cm column; gradient ((time, %acetonitrile), (0, 10), (3, 30), (25, 55), (26, 
10))) Rt 12.6 minutes. 
Amino Acid Analysis (acid hydrolysate; 24 h) after purification by: 
Gel Anion: Cation: Prep. 
Filtration Exchange HPLC Ideal 
Asx 6.67 6.86 6.47 6.08 6 
Thr 2.20 2.01 2.15 1.98 2 
Ser 3.43 3.86 3.70 3.74 4 
GIx 3.78 4.08 3.58 3.43 3 
Pro 2.88 2.55 2.61 3.19 2 
Gly 1.43 1.15 1.15 1.12 1 
Ala 1.67 2.19 2.15 2.12 2 
Val 2.29 2.86 2.70 2.57 3 
Met 1.16 1.02 0.95 0.86 1 
Ile 0.78 0.93 0.96 0.96 1 
Leu 3.36 3.30 3.25 2.95 3 
Tyr 0.82 1.04 0.95 0.92 1 
Phe 1.57 2.04 2.06 1.95 2 
His 1.25 0.90 0.93 0.89 1 
Trp 0.56 0.73 0.69 0.92 1 
Lys 2.03 1.83 1.65 1.74 1 
Arg 2.51 2.39 2.37 2.07 2 
Total lerrorl 8.15 5.14 4.56 3.01 
Mean lerrorl 22.6% 14.3% 12.6% 8.4% 
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Ala-i 24-Interleukin-i -3-Precursor 102-138 (121) 
H- Pro- I le- Phe-Phe-Asp-Thr-Trp-Asp-Asn-G lu-Ala-Tyr-VaI-His-Asp-Ala-Pro-
Met-Ser-Gly-OH 
The initial resin was Fmoc-Gly-(0.6 mmol g -1 ; 0.85 g, 0.5 mmol). The 
side-chain amide groups of asparagine and glutamine were left unprotected. 
Histidine was protected with a butoxymethyl group on the it-nitrogen of the 
imidazole ring (His-(Bum)). The weight of peptide-resin after chain 
assembly was 3.03g. Resin-bound peptide was cleaved for 1.5 h with a 
solution of 5% ethanedithiol, 2.5% anisole, 2.5% ethyl methylsulphide, 2.5% 
phenol, and 5% water in TFA (10 cm 3), giving crude peptide (0.27 g) as a 
white solid. A portion (0.16 g) of this material was ground in acetic acid (2 
cm3) and water (2 cm 3) added. This mixture was sonicated for 20 minutes 
at 35°C and a further portion of water (2 cm 3) added. A small amount of 
insoluble material was removed by filtration. The residue was washed with 
a further portion of water (2 cm 3). The combined washings and filtrate were 
purified in three portions by preparative HPLC (28x2.5 cm diam. column; 
flow 7 cm3/minute; gradient [(time, %acetonitrile), (0, 0), (5, 20), (35, 60), 
(38, 90), (39, 0)]). Fractions were analysed by HPLC and combined and 
lyophilised as appropriate. The title compound was obtained as the major 
product (20.6 mg). 
FAB-MS m/z 4209.4; C186H2N51059S requires 4209.7; HPLC (gradient 
A) Rt 15.1 minutes; Amino acid analysis Asx65.82, Thr11.03, Ser44.00, 
G1u43.67, Pr021.95, G1y11.20, Ala33.25, Va132.61, Met10.98, lIe10.78, 
Leu32.83, Tyr10.94, Phe22.02, His10.82, Lys11.12, Arg21.36, Trp11.11. 
600 MHz 1 H NMR (30%CD30H, 65%H20, 5%D20) 
Residue a-CH 	a-NH 3-CH 	others 
102-Pro 4.44 	N/A 2.02,2.33 y2.1 0;83.68,3.82 
103-Ile 4.21 8.43 1.75 	)'CH2:1.15,1.44; 
'CH3:0.89; 6CH3:0.78 
1 04-Phe 8.27 
IDI:] 
105-P he 
106-Asp 	4.62 	8.35 	2.77,2.90 
107-Thr 4.26 7.94 4.20 	yl.14 
1 08-Trp 	 indole 2H:7.34; 4H:7.69; 




111-Glu 4.31 8.19 2.05,2.14 -12.50 
112-Ala 4.24 8.12 1.62 
113-Tyr 4.60 7.87 2.97,3.13 2H:7.40; 4H:7.17 
114-Val 4.04 7.79 2.06 	O.87,0.95 
115-His 8.44 3.22,3.36 2H:7.40; 4H:8.71 
116-Asp 
117-Ala 
118-Pro 4.51 2.02,2.33 y2.10; 53.68,3.82 
119-Val 4.13 8.17 2.12 	0.97,1.03 





125-Thr 4.39 8.08 4.31 	y1.27 






132-Lys 4.40 8.33 1.86,1.94y1.54;51.76;c3.07; 
NH :7.62 
1 33-Ser 
134-Leu 4.44 8.28 1.61 	yi.61;50.96,1.01 
135-Val 4.17 8.03 2.15 y1.00,1.03 
136-Met • 4.63 8.41 2.08,2.20 y2.63,2.71 
1 37-Ser 
138-Gly 3.94 8.41 
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Interleukin-1 -u-Precursor 101-112 (122) 
H-Glu-Pro- l le- P he- Phe-Asp-Thr-Trp-Asp-Asn-G lu-Ala-OH 
The initial resin was Fmoc-Ala-(0.48 mmol g 1 ; 1.04 g, 0.5 mmol). The 
side-chain amide group of asparagine was left unprotected. The weight of 
peptide-resin after chain assembly was 1.55 g. Resin-bound peptide (0.5 g) 
was cleaved for 1.5 h with a solution of 5% thioanisole and 5% water in TFA 
(20 cm3), giving crude peptide (0.19 g). Crude peptide (0.15 g) was 
dissolved in 50% aqueous acetonitrile (10 cm 3) and purified in 10 portions 
by preparative HPLC (11 cm column; flow 5 cm 3/minute; [(time, 
%acetonitrile), (0, 10), (25, 45), (26, 90), (27, 10)]). Appropriate fractions 
were combined and lyophilised. The main fraction contained purified 
peptide (0.047 g). The presence of a small amount of contaminating 
material was detected by analytical HPLC of this product. The peptide was 
redissolved in 50% aqueous acetonitrile (3 cm .  3) and further purified in 10 
portions by preparative HPLC (11 cm column; flow 5 cm 3/minute; isocratic 
24% acetonitrile). Lyophilisation of the appropriate fractions gave the title 
compound as a fluffy white solid (6 mg). 
FAB-MS m/z 1483.4; C691­190N140 requires 1483.6; Analytical HPLC 
(gradient B) Rt 10.0 minutes; Amino acid analysis (acid hydrolysis; 18 h) 
Asx33.07, Thr1l.03, Glu22.17, Pro10.96, A1a10.99, lle10.83, Phe2l.77, 
Trp1l.16. 
This peptide was also prepared using side-chain protected asparagine 
derivatives in the same manner. The products of these syntheses were not 
isolated. 
Amino-acid analysis of IL-1 -p-pre 101-112 peptide-resin prepared using 
Fmoc-Asn-(trityl)-OH (acid hydrolysis; 18 h) Asx32.89, Thr1 1.03, Glu21 .98, 
Pro1 n.d., Ala1 1.16, 11e10.70, Phe2l .65, Trp1 1.24. 
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Acetyl-lnterleukin-1 -13-Precursor  106-117 (123) 
Ac-Asp-Th r-Trp-Asp-Asn-G lu-Ala-Tyr-Val-His-Asp-Ala-OH 
The initial resin was Fmoc-Ala-(0.48 mmol g 1 ; 1.04 g, 0.5 mmol). The 
side-chain amide group of asparagine was left unprotected. Histidine was 
protected with a trityl group on the t-nitrogen of the imidazole ring (His-
(Trt)). The weight of peptide-resin after chain assembly was 1.69g. 
Peptide-resin (0.4 g) was cleaved for 1.5 h with a solution of 2.5% ethane-1, 
2-dithiol (EDT), 5% thioanisole, and 5% water, in TFA (10 cm 3) to give 
crude peptide (0.13 g). Crude peptide (0.10 g) was dissolved in acetic acid 
(1.2 cm3) and water (0.8 cm 3) added. This solution was passed in 20 
portions down an 11 cm semi-preparative HPLC column eluted with 15% 
aqueous acetonitnle. Appropriate fractions were combined and lyophilised 
to give three products. 
Product 1: FAB-MS: m/z 1477.6; CHN16025 requires 1477.4; Analytical 
HPLC (gradient E) Rt 9.2 minutes. 
Product 2: FAB-MS: m/z 1477.6; Analytical HPLC (gradient E) Rt 9.2 
minutes (50%),12.0 minutes (50%). 
Product 3: FAB-MS: m/z 1477.6; Analytical HPLC (gradient E) Rt 12.0 
minutes. 
Amino acid analysis (acid hydrolysis; 18 h): 
Product: 
1 	2 	3 	Ideal 
Asx 3.93 3.91 3.93 	4 
Thr 0.87 0.88 0.86 1 
GIx 1.03 1.04 1.07 	1 
Ala 2.02 2.03 2.07 2 
Val 0.97 0.98 0.98 	1 
Tyr 1.22 1.20 1.18 1 
His 0.97 0.96 0.90 	1 
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Amino acid analysis (proteolytic digestion): 
Product 
1 2 3 Ideal 
Asp 0.15 0.62 0.98 2 
Thr 0.32 0.52 0.48 1 
Glu 0.50 0.91 0.83 1 
Ala 2.00 2.00 2.00 2 
Val 0.30 1.97 1.60 1 
Tyr 2.57 3.40 3.10 1 
His 0.24 1.70 1.40 1 
600 MHz 1 H NMR on product 3 (90%H20, 10%D20) 
Residue a-CH a-NH 13-CH 	others 
106-Asp 4.29 7.61 2.32,2.45 
107-Thr 3.87 7.59 3.61 	yO.76 
108-Trp 4.29 7.51 2.92,2.92 indole 211:6.95; 4H:7.25; 
5H:6.81; 61-1:6.87; 
71-1:7.12 
109-Asp 4.23 7.62 2.32,2.45 
11 0-Asn 4.22 7.67 2.41,2.47 
111 -Glu 3.87 7.73 1.64,1.72 -y2.12 
112-Ala 3.82 7.65 0.94 
11 3-Tyr  4.16 7.38 2.64,2.73 2,61-1:6.44; 3,51-1:6.73 
11 4-Val 3.61 7.30 1.65 
11 5-His 4.31 7.93 2.82,2.95 21-1:6.95; 41-1:8.21 
116-Asp 4.36 7.94 2.50,2.60 
117-Ala 3.99 7.78 1.09 
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I nterleu kin-i -p-Precursor 111-122 (124) 
H-Glu-Ala-Tyr-Val-His-Asp-Ala-Pro-Val-Arg-Ser-Leu-OH 
The initial resin was Fmoc - Leu. ® (0.59 mmcl g 1 ; 1.03 g, 0.60 mmcl). 
Histidine was protected with a trityl group. The weight of peptide-resin after 
chain assembly was 1.70g. Resin-bound peptide (0.4 g) was cleaved for 
1.5 h with a solution of 5% thioanisole and 5% water in TFA (20 cm 3), giving 
crude peptide (0.16 g). Crude peptide (0.10 g) was dissolved in 0.1% 
aqueous TEA (5 cm 3), filtered to remove a small amount of insoluble 
material and purified in 6 portions by preparative HPLC (11 cm. column; 
flow 10 cm3/minute; gradient: (time, % acetonitrile) (0, 10), (1, 13), (9, 13), 
(12, 90), (14, 90), (16, 10)). Lyophilisation of the appropriate fractions gave 
the title compound as a fluffy white solid (42 mg). 
FAB-MS (HRMS) m/z 1356.69111; CH94N17O19 requires 1356.69113; 
Analytical HPLC (gradient B) At 13.4 minutes; (gradient D) Rt 14.2 minutes; 
Amino acid analysis (acid hydrolysis; 18 h) Asx11.01, Ser10.87, G1u11.13, 
Pro1l.01, A1a22.07, Va122.00, Leu1l.03, Tyr10.97, His11.01, Arg10.95; 
Sequencing gave unambiguous identification of the expected amino acid at 
each cycle. 
600 MHz 1 H NMR (90%H20, 10%D20) 
Residue a-CH a-NH 	-CH 	others 
111-Gtu 4.02 
112-Ala 4.36 
11 3-Tyr 4.58 









11 9-Val 4.05 8.26 
1 20-Arg 4.38 8.44 
121-Ser 4.45 8.37 
122-Leu 4.37 8.36 
2.08,2.10 y2.46 
1.39 
2.88,2.88 2,61-1:6.79; 3,5H:7.09 
	
1.94 	'O.83 
3.14,3.24 21-1:7.31; 4H:8.60 
2.77,2.87 
1.38 
1.90,2.29 ,y2.08; 83.64,3.81 
2.04 	)0.93 
1.80,1.88 yl .62; 63.20; NH:7.20 
3.84,3.84 








Acetyl-Interleukin-1 -n-Precursor 111-122-NH2 (125) 
Ac-G lu-Ala-Tyr-Val-His-Asp-Ala-Pro-Val-Arg-Ser-Leu-N H2 
The initial resin was 5-(Fmoc-amino)-dibenzosuberyl-resin (0.74 mmol g 1 ; 
0.54 g, 0.40 mmol). Histidine was protected with a trityl group. The weight 
of peptide-resin after chain assembly was 1.05g. Resin-bound peptide 
(0.25 g) was cleaved for 2 h with a solution of 5% anisole and 5% water in 
TEA (20 cm3), giving crude peptide (0.12 g). Crude peptide (0.042 g) was 
dissolved in 10% aqueous acetonitrile (4 cm 3) and purified in 8 portions by 
preparative HPLC (11 cm. column; flow 3 cm 3/minute; gradient: (time, % 
acetonitrile) (0, 15), (14, 20), (15, 15). Lyophilisation of the appropriate 
fractions gave three products as fluffy white solids. 
Product 1: FAB-MS: m/z 	1396.8; C621­196N18019 requires 1396.7; 
Analytical HPLC (gradient D) At 8.2 minutes (95%), 9.3 minutes (5%). 
Product 2: FAB-MS m/z 1396.8; Analytical HPLC (gradient D) Rt 8.2 
minutes (50%), 9.3 minutes (50%). 
Product 3: FAB-MS m/z 1396.8; Analytical HPLC (gradient D) Rt 8.2 
minutes (3%), 9.3 minutes (97%). 
Amino acid analysis (acid hydrolysis; 18 h): 
Product: 
1 	2 	3 	Ideal 
Asx 1.02 1.06 1.06 	1 
Ser 0.93 0.94 0.98 1 
Glx 1.15 1.12 1.12 	1 
Pro 1.04 0.99 0.95 1 
Ala 2.04 1.96 2.08 	2 
Val 1.34 1.39 1.35 2 
Leu 1.11 0.97 0.97 	1 
Tyr 0.99 0.91 0.89 1 
His 0.72 0.71 0.70 	1 
Arg 0.84 1.03 0.78 1 
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Amino acid analysis (proteolytic digestion): 
Product: 
1 	2 	3 	Ideal 
Asx 0.55 0.34 1.09 	1 
Ser 1.93 2.05 1.18 1 
Pro ---- ---- 0.71 	1 
Ala 0.60 0.53 0.74 2 
Val 1.94 1.92 2.26 	2 
Leu 1.94 2.47 2.26 1 
Tyr 1.24 0.91 1.63 	1 
His 0.41 0.17 1.00 1 
Arg 1.43 1.61 1.14 	1 
600 MHz 1 H NMR of product 1 (90%H20, 10%D20) 
Residue a-CH a-NH 	13-CH 	others 
111 -Glu 4.38 8.29 1.97,2.08 y2.52 
112-Ala 4.37 8.36 1.35 
113-Tyr 4.69 8.00 2.97,3.07 2,6H:6.85; 3,5H:7.07 
114-Val 4.10 8.10 1.96 	O.80,0.92 
115-His 4.80 8.70 3.22,3.37 21-1:7.40; 4H:8.70 
116-Asp 4.80 8.51 2.77,2.91 
117-Ala 4.51 8.27 1.37 
118-Pro 4.48 1.93,2.27 'y2.06; 83.59,3.70 
119-Val 4.14 8.24 2.10 	y1.04 
120-Arg 4.38 8.44 1.83,1.83 y1.78; 	3.28; NH:7.20 
121-Ser 4.53 8.39 3.94,3.94 
122-Leu 4.42 8.40 1.75 	yl.75;0.96,11.03 
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600 MHz 1 H NMR on product 3 (90%H20, 10%D20) 
Residue a-CH a-NH others 
111-Glu 4.26 8.28 1.93,2.04 y2.45 
112-Ala 4.25 8.34 1.27 
11 3-Tyr  4.57 8.00 2.94,3.04 2,61-1:6.87; 3,51-1:7.26 
114-Val 4.00 7.90 1.96 	yO.86 
115-His 4.70 8.57 3.17,3.26 21-1:7.12; 41-1:7.56 
116-Asp 4.65 8.48 2.77,2.87 
117-Ala 4.57 8.22 1.36 
118-Pro 4.45 1.87,2.27 y2.03; 83.64,3.78 
1 19-Val 4.06 8.25 2.05 	095 
120-Arg 4.38 8.44 1.77 1 1.85y1.63; 63.21; NH:7.20 
121 -Ser 4.47 8.38 3.87,3.87 
1 22-Leu 4.35 8.41 1.67 	yl .67;ö 0.88,0.95 
N-(N', N'-dimethyl-5-aminonaphthalenesulphonyl)-1 1-  
amino undecanoyl-lnterleukin-1 -3-Precursor 111-122(126) 
Dansyl-aminouridecanoyl-Glu-Ala-Tyr-Val-His-Asp-Ala-Pro-Val-Arg-Ser-
Leu-OH 
Peptide-resin (Ca. 0.5 mmol) was prepared as for lnterleukin-1 - 13-Precursor 
111-122. Following removal of the N-terminal Fmoc group the resin was 
treated with a solution of Fmoc-aminoundecanoic acid (0.806 g, 2.0 mmol), 
HOBt (0.27 g, 2.0 mmol), and DIC (0.26 g, 2.0 mmol) in DMF (16 cm 3) 
which had been allowed to react at room temperature for 15 minutes. The 
mixture was sonicated for 1 hour then filtered and washed thoroughly with 
DMF. After removal of the Fmoc group one quarter of the peptide resin was 
treated with a solution of dansyl chloride (1.1 g, 4.0 mmol) in DMF (15 cm 3). 
The mixture was sonicated for 1 hour then filtered. The resin was washed 
well with DMF then diethyl ether and dried to give dansyl-aminoundecanoyl-
peptide-resin (0.46 g). The resin gave a strong yellow-green fluorescence 
when placed under a UV lamp emitting at 366 nm. Peptide-resin (0.2g) was 
cleaved for 1.5 h with a solution of 5% anisole and 5% water in TFA (10 
cm3), giving crude peptide (0.087 g). Crude peptide (0.080 g) was 
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dissolved in 20% aqueous acetonitrile (6 cm 3) and purified in 6 portions by 
preparative HPLC (22 cm column length, flow 7 cm 3/minute, gradient (time, 
%acetonitnle): (0, 15), (20, 50), (21, 15)) to give two products. 
Product 1 (title compound and epimer containing D-His): 11.2 mg; FAB-MS 
m/z 1772.9; CH125N190S requires 1772.4; kmax 202 nm (100%), 222 
(76), 283 (6.6), 320 (2.0); Analytical HPLC (gradient A) Rt 12.3 minutes 
(50%), Rt 12.6 minutes (50%). 
Product 2 (aminoundecanoyl-IL-1-3-pre-111-122 and epimer containing D-
His); 12.4 mg; FAB-MS m/z 1539.9; C71H115N18020 requires 1539.3; kmax 
(20% aqueous acetonitrile) 202 nm (87% relative to A202 for product 1), 
277 (1.7); Analytical HPLC (gradient A) Rt 9.6 minutes (50%), Rt 9.9 
minutes (50%). 
InterIeukin-1--Precursor 117-128 (127) 
H-Ala-Pro-Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-OH 
The initial resin was FmocAsp(O tBu)J(0 . 58  mmol g 1 , 1.02 g, 0.50 
mmol). The side-chain amide group amide group of asparagine was left 
unprotected. The thiol group of cysteine was protected with the trityl group. 
The weight of peptide-resin after chain assembly was 1.59 g. Resin-bound 
peptide (0.3 g) was cleaved for 1.5 h with a solution of 5% EMS, 5% 
thioanisole and 5% water in TFA (10 cm 3), giving crude peptide (0.08 g). 
Crude peptide (0.08 g) was dissolved in 50% aqueous acetonitrile (5 cm 3), 
and purified in 5 portions by preparative HPLC (11 cm. column; flow 5 
cm3/minute; gradient: (time, % acetonitrile) (0, 15), (20, 50), (21, 15)). 
Lyophilisation of the appropriate fractions gave the title compound as a fluffy 
white solid (0.013 g). 
FAB-MS m/z 1344.4; CH97N19O18S requires 1344.6; Analytical HPLC 
(gradient A) At 11.2 minutes; Amino acid analysis (acid hydrolysis; 18 h) 
Asx22.03, Thr1 1.10, Ser1 1.12, Pro1 1.40, Cys10.42, Ala10.93, Val10.91, 
Leu22.30, Arg22.08. 
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Acetyl-lnterleukin-1 -p-Precursor 117-128-NH 2 (129) 
Ac-Ala-Pro-Val-Arg-Ser-Leu-Asn-Cys-Th r-Leu-Arg-Asp-N H2 
The initial resin was 5-(Fmoc-amino)dibenzosuberyl-2-resin (0.65 mmol g -1 ; 
0.82 g, 0.53 mmol). Cysteine was protected with a trityl group on the side-
chain thiol group. The weight of peptide-resin after chain assembly was 
2.42g. Resin-bound peptide (0.5 g) was cleaved for 2 h with a solution of 
5% thioanisole, 5% EDT, and 5% water in TFA (10 cm 3), giving crude 
peptide (0.16 g). Crude peptide (0.16 g) was dissolved in 50% aqueous 
acetic acid (10 cm 3), filtered to remove a small amount of insoluble material 
and purified in 6 portions by preparative HPLC (11 cm. column; flow 5 
cm3/minute; gradient: (time, % acetonitnle) (0, 10), (13, 25), (15, 50), (17, 
50), (18, 10)). Lyophilisation of the appropriate fractions gave the title 
compound as a fluffy white solid (0.06 g). 
FAB-MS m/z 1385.5; C57H100N018S requires 1385.6; Analytical HPLC 
(gradient A) At 9.7 minutes; Amino acid analysis (acid hydrolysis; 18 h) 
Asx22.01, Thr10.91, Ser10.82, Pro1 1.74, Ala1 1.10, Cys10.38, Val1 1.00, 
Leu22.05, Ar922.01. 
600 MHz 1 H NMR (90%H20, 10%D20) 
Residue a-CH a-NH 3-CH 	others 
117-Ala 4.55 8.10 1.24 
118-Pro 4.40 1.78,2.19 yl.95; 	3.54,3.73 
119-Val. 3.96 8.16 1.96 	70.85 
120-Arg 4.28 8.33 1.67,1.76 yl.53; 	3.12; NH:7.10 
121 -Ser 4.34 8.23 3.76,3.76 
122-Leu 4.26 8.28 1.54 	yl.54;80.78,0.85 
123-Asn 4.61 8.34 2.68,2.76 NH:6.83,7.52 
124-Cys 4.47 8.20 2.87,2.87 
125-Thr 4.20 8.18 4.14 	y1.12 
1 26-Leu 4.25 8.06 1.53 y1.53; 	0.78,0.85 
127-Arg 4.22 8.22 1.67,1.76 yl.53;83.12,3.12; 
NH:7.10 
128-Asp 4.59 8.25 2.76,2.84 
118 
Interleukin-1 -f3-Precursor 121-132(130) 
H-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-G ln-Gln-Lys-OH 
The initial resin was Fmoc- Lys- (Boc).((0.44 mmol g 1 ; 0.90 g, 0.40 mmol). 
The side-chain amide groups of asparagine and glutamine were left 
unprotected. The thiol group of cysteine was protected with the trityl group. 
The weight of peptide-resin after chain assembly was 1.80g. Resin-bound 
peptide (0.5 g) was cleaved for 1.5 h with a solution of 5% EDT, 5% 
thioanisole and 5% water in TEA (10 cm 3), giving crude peptide (0.26 g). 
Crude peptide (0.24 g) was dissolved in acetic acid (0.1 cm 3) and water (0.5 
cm3) added. This solution was purified in 10 portions by preparative HPLC 
(11 cm. column; flow 5 cm3/minute; gradient: (time, % acetonitrile) (0, 10), 
(20, 30), (21, 10)). Lyophilisation of the appropriate fractions gave the title 
compound as a fluffy white solid (0.052 g). 
FAB-MS m/z 1393.2; CHN19021S requires 1392.6; Analytical HPLC 
(gradient (0, 10), (25, 44), (26, 10)) Rt 7.7 minutes; Amino acid analysis 
(acid hydrolysis; 18 h) Asx22.06, Thr 1 1.07, Ser2l .93, G1x22.02, Leu21 .95, 
Lys1l.1 1, Arg1O.88. 
600 MHz 1 H NMR (90%H20, 10%D20) 







1.63 ?1 .63; 80.88,0.96 
1.75,1.84 y1.60;63.18; NH:7.18 
2.88,2.97 
3.88,3.92 
1.99,2.15 ,y2.38; NH:7.18,7.52 
1.99,2.12 'y2.39; NH:7.18,7.52 





























132-Lys 4.35 8.42 
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Two other partial syntheses of this peptide were carried out using the side-
chain amide protected g lutamine derivatives Fmoc-G I n-(dibenzosuberenyl)-
OH and Fmoc-Gln-(Trt)-OH. On each occasion the synthesis was 
suspended after the coupling of Asp-1 28. Neither cleavage of the resulting 
peptide-resin nor isolation of the product were carried out on either 
occasion. 
Acetyl-1 nterleukin-1 -13-Precursor  127-138(131) 
Ac-Arg-Asp-Ser-G ln-G ln-Lys-Ser-Leu-Val-Met-Ser-G ly-OH 
The initial resin was Fmoc-Gly-(0.51 mmol g -1 ; 1.00 g, 0.51 mmol). The 
side-chain amide group of glutamine was left unprotected. Coupling cycles 
were modified to allow the use of 1-hydroxy-4-ethoxycarbonyl-5-
methyltriazole as an activating reagent 165. This was used in exactly the 
same manner as HOBt (section 3.2.4ii). The weight of peptide-resin after 
chain assembly was 1.40 g. Resin-bound peptide (0.5 g) was cleaved for 
1.5 h with a solution of 5% EDT, 5% EMS, 5% thioanisole and 5% water in 
TFA (10 cm 3), giving crude peptide (0.29 g). Crude peptide (0.07 g) was 
dissolved in 50% aqueous acetonitrile (1.5 cm 3). This solution was purified 
in 10 portions by preparative HPLC (11 cm. column; flow 3.5 cm 3/minute; 
gradient: (isocratic conditions: 11% acetonitrile)). Lyophilisation of the 
appropriate fractions gave the title compound as a fluffy white solid. (0.011 
g). 
FAB-MS m/z 1377.4; C65HN18021S requires 1377.6; Analytical HPLC 
(gradient A) Rt 7.3 minutes; Amino acid analysis (acid hydrolysis; 18 h) 
Asx10.72, Ser32.65, G1x22.23, G1y1 1.10, Va11 1.09, Met1 1.11, Leu1 1.09, 
Lys1 1.02, Arg1O.65. 
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600 MHz 1 H NMR (90%H20, 10%D20) 
Residue a-CH cc-NH -CH 	others 
127-Arg 4.25 8.35 1.74,1.80 yl.66; 83.18; NH 7.18 
128-Asp 8.59 2.82,2.94 
129-Ser 4.54 8.30 3.85 
130-Gin 4.27 8.30 1.97,2.08 'y2.34 
131-Gin 4.31 8.37 1.98,2.11 y2.34 
132-Lys 4.31 8.37 1.75,1.83 yl .44;S1 .66;c2.96; 
NH:7.18 
133-Ser 4.40 8.28 3.94 
134-Leu 4.37 8.29 1.62 	yl.62;0.87,0.91 
135-Val 4.08 8.06 2.05 O92 
136-Met 4.55 8.47 2.00,2.11 y2.52,2.61 
137-Ser 4.49 8.31 3.85 




Na9FluorenylmethoxycarbonylLgiutamine (5.0 g, 13.6 mmol) and 5H-
dibenzo[a,d]cyclohepten-5-ol (3.0 g, 14.4 mmol) were suspended in acetic 
acid (250 cm3) and conc. sulphuric acid (0.3 cm 3) added. The bright pink 
mixture was stirred for 30 h, during which time a pale pink precipitate 
formed and the colour of the mixture faded considerably. After filtration the 
wet solid was resuspended in EtOAc (300 cm 3) and stirred for 2 h, then 
filtered again and washed with EtOAc (400 cm 3), water (until the filtrate was 
neutral to litmus paper), and diethyl ether (250 cm 3). The resulting white 
solid was dried in vacuo to give the title compound (6.6 g; 87%). 
M.P. 215-219°C; TLC-A: At 0.78; [a]D25  (c=1, DMF) -12.1°; FAB-MS:. 
m/z=559 (5%), 191 (100%); HAMS m/z 559.22328; C351 ­131N205 requires 
559.22333; ?m (DMF) 267 (e26, 000), 277 (24, 000), 288 (17, 000), 300 
nm (15, 000 mol 1 dm3cm 1 ); Vm  (KBr disc) 3300 (s, COOH, NH), 3030 (w, 
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arom. CH str.), 2940 (w, aliph. CH str.), 1690 (s, urethane C=O), 1640 (s, 
amide), 1530, 730 cm -1 (s, arom. OH bend); 8H  (80 MHz, DMSO-d6) 9.0 (d, 
J=9Hz, 1H, amide NH), 7.2-7.9 (m, 16H, aromatic CH), 7.1 (s, 2H, CH=CH), 
5.6 (d, J=8Hz, 1 H, urethane NH), 4.2 (bm, 4H, Fmoc CHOH2 Dbse OH), 4.0 
(b, .1 H, aCH), 2.4 (m, 2H, 'CH2), 1.9 (m, 2H, 3CH2); S c (DMSO-d6) 173.8 (q, 
000H), 171.0 (q, amide), 156.3 (q, urethane), 143.9-133.6 (4 peaks, q, 
arom.), 131.3-120.3 (9 peaks, CH aromatic), 65.8 (OH2, Fmoc), 53.7 (aCH), 




Na9Fluorenyl met hoxycarbonylLasparagine (4.81 g, 13.6 mmcl) and 5H-
dibenzo[a,d]cyclohepten-5-ol (3.0 g, 14.4 mmol) were suspended in acetic 
acid (250 cm3) and conc. sulphuric acid (0.3 cm 3) added. The bright pink 
mixture was stirred for 30 h, during which time a pale pink precipitate 
formed and the colour of the mixture faded considerably. After filtration the 
wet solid was resuspended in EtOAc (300 cm 3) and stirred for 2 hours, then 
filtered again and washed with EtOAc (400 cm 3), water (until the filtrate was 
neutral to litmus paper) and diethyl ether (250 cm 3). The resulting white 
solid was dried in vacuo to give the title compound (6.3 g;85%). 
M.p. 212-214°C; TLC-A: Rf 0.65; [a]D25  (c=1, DMF) -10.0° ; FAB-MS: 
m/z=545 (5%), 191 (100%); HRMS m/z 545.20766; CH29N205 requires 
545.20763; Amax  (DMF) 266 (e27, 000), 277 (24, 000), 288 (17, 000), 300 
nm (15, 000 mol 1 dm3cm 1 ); Vm  (KBr disc) 3300 (s, COOH, NH), 3030 (w, 
arom. CH str.), 2940 (w, aliph. CH str.), 1690 (s, urethane 0=0), 1640 (s, 
amide), 1530, 730 cm -1 (s, arom. OH bend); 6H  (80 MHz, DMSO-d6) 9.0 (d, 
J=9Hz, 1H, amide NH), 7.2-7.8 (m, 16H, aromatic OH), 7.1 (s, 2H, OH=CH), 
5.6 (d, J=9Hz, 1H, urethane NH), 4.3 (b, 1H, czCH), 4.1 (b, 4H, Fmoc 
OHCH2, Dbse OH), 2.7 (m, 2H, 13OH2); 8c (DMSO-d6) 173.3 (q, COOH), 
168.9 (q, amide), 156.0 (q, urethane), 143.9-133.6 (4 peaks, q, arom.), 
131.4-120.3 (9 peaks, CH aromatic), 65.9 (OH2, Fmoc), 50.8 (ccOH), 46.8 





Na9FluorenylmethoxycarbonylLglutamine (1.60 g, 4.3 mmol) and 10, 11 
dihydro-5H-dibenzo[a,d]cyclohepten-5-ol (1.76 g, 8.4 mmol) were 
suspended in acetic acid (40 cm 3) and conc. sulphuric acid (0.075 cm 3 ) 
added. The mixture was stirred for 30 h, during which time a precipitate 
formed. The mixture was poured into a stirred mixture of EtOAc/water (1:1; 
150 cm3) then filtered. The resulting solid was washed thoroughly with 
EtOAc and cyclohexane then dried in vacuo to give the title compound (1.9 
g; 78%). 
M.p. 204-205°C; TLC-A: Rf 0.78; [x]0 25 (c=1, DMF) -4.00  ; FAB-MS: 
m/z=561 (7%), 193 (100); HRMS m/z 561.23891; C35HN205 requires 
561.23893; Xmax  (DMF) 266 (e13, 000), 289 (4, 500), 300 nm (5, 200 mol 
ldm3cml); Vm (KBr disc) 3300 (s, COOH, NH), 3030 (w, arom. CH str.), 
2940 (w, aliph. CH str.), 1690 (s, urethane C=O), 1640 (s, amide), 1540 (s, 
amide), 1270(s), 730 cm -1 (s, arom. CH bend); oH (80 MHz, DMSO-d6) 9.0 
(d, J=9Hz, 1H, amide NH), 7.2-7.8 (m, 16H, aromatic CH), 6.4 (d, J=9Hz, 
1H, urethane NH), 4.2 (b, 4H, Fmoc CHCH2, Dbsa CH), 4.0 (b, 1H, aCH), 
3.1 (s, 4H, Dbsa CH2CH2), 2.4 (m, 2H, yCH2), 1.9 (m, 2H, 3CH2). 
N-9-FIuorenyImethoxycarbonyI-N! 3-(1 0,11 -dihydro-5H-
dlbenzo[a,d]cyclohepten-5-yI)-L-asparagine (111) 
Fmoc-Asn-(Dbsa)-OH 
Na9FluorenylmethoxycarbonyILasparagine (0.40 g, 1.1 mmol) and 10, 
11 -dihydro-5H-dibenzo[a,d]cyclohepten-5-ol (0.24 g, 1.1 mmol) were 
suspended in acetic acid (20 cm3) and conc. sulphuric acid (0.02 cm 3) 
added. The mixture was stirred for 30 h, during which time a precipitate 
formed. The mixture was poured into a stirred mixture of EtOAc/water (1:1; 
123 
100 cm3) then filtered. The resulting solid was washed thoroughly with 
EtOAc and cyclohexane then dried in vacuo to give the title compound 
(0.46 g; 74%). 
M.P. 210-214°C; TLC-A: Rf 0.75; [a]0 25 (c=1, DMF) -3.20  ; FAB-MS: 
m/z=547 (5%), 193 (100); HRMS 547.22332; CH31N205 requires 
547.22328; kmax (DMF) 268 (c=14, 000), 289 (4, 500), 300 nm (5, 300 mol -
1 dm3cm 1 ); vm (KBr disc) 3300 (s, COOH, NH), 3020 (w, arom. CH str.), 
2940 (w, aliph. CH str.), 1690 (s, urethane C=O), 1640 (s, amide), 1540 (s, 
amide), 1240 (s), 730 cm -1 (s, arom. OH bend); oH (80 MHz, DMSO-d6) 9.0 
(d, J=9Hz, 1H, amide NH), 7.2-7.8 (m, 16H, aromatic OH), 6.4 (d, J=9Hz, 
1H, urethane NH), 4.4 (b, 1H, aCH), 4.2 (b, 4H, Fmoc CHCH2, Dbsa CH), 




(0.53 g, 1.2 mmol) 
and 5H-dibenzo[a,d]cyclohepten-5-ol (0.28 g, 1.2 mmol) were dissolved in 
acetic acid (3.0 cm 3) and conc. sulphuric acid (0.02 cm 3) added. The bright 
orange solution was stirred for 20 h, during which time a pale pink 
precipitate formed and the colour of the mixture faded considerably. After 
filtration the solid was washed with EtOAc (20 cm 3), water (until the filtrate 
was neutral to litmus paper) and diethyl ether (20 cm 3). The resulting white 
solid was dried in vacuo to give the title compound (0.46 g;60%). 
M.P. 165-172°C; TLC-A: Rf 0.73; [a]025  (c=0.5, DMF) -2.5 0 ; FAB-MS: 
m/z=651 (6%), 191 (100%); HRMS m/z 651.20905; C35H31N409 requires 
651.20908; ?m (MeOH) 279 nm (e=28, 000 mol -1 dm3cm-1 ); Vmax  (KBr 
disc) 3300 (s, COOH, NH), 3040 (w, arom. OH str.), 2960 (w, aliph. OH str.), 
1700 (s, urethane C=O), 1640 (m, amide), 1520 (s, C-NO2), 1340 cm -1 (s, 
C-NO2); 5H  (80 MHz, CDCI3) 8.1 (d, J=8Hz, 4H, Bnpeoc 3, 5H), 7.2-7.5 (m, 
12H, Bnpeoc 2, 4H Dbse CH), 7.1 (s, 2H, CH=CH), 6.1 (d, J=8Hz, 1H, 
urethane NH), 4.5 (bm, 4H, Bnpeoc CHCH2, Dbs CH), 4.1 (m, 1H, aCH), 
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2.1 (m, 2H, CH2), 1.9 (m, 2H, 13CH2); ö (DMSO-d6) 175.7 (q, 000H), 
171.5 (q, amide), , 155.6 (q, urethane), 146.7-133.1 (4 peaks, q, arom.), 
131.3-120.3 (7 peaks, CH aromatic), 65.8 (CH2, Bnpeoc), 53.2 (aCH), 49.3 
(CH, Fmoc), 31.9 ('CH2), 27.2 (CH2), 20.1 (CH, Dbse). 
N—(2,2-Bis(4-nitrophenyl)ethoxycarbonyl-Nt 3-(5H-
dibenzo[a,d]cyclohepten -5-yl)-L-asparagine (113) 
Bnpeoc-Asn-(Dbse)-OH 
Na—(2,2-Bis(4-nitrophenyl)ethoxycarbonyl)-L-asparagine (0.60 g;1.3 mmol) 
and 5H-dibenzo[a,d]cyclohepten-5-ol (0.28;1.3 mmol) were dissolved in 
acetic acid (3.0 cm3) and conc. sulphuric acid (0.02 cm 3) added. The bright 
orange solution was stirred for 20 h, during which time a pale pink 
precipitate formed and the colour of the mixture faded considerably. After 
filtration the solid was washed with EtOAc (20 cm 3), water (until the filtrate 
was neutral to litmus paper) and diethyl ether (20 cm 3). The resulting white 
solid was dried in vacuo to give the title compound (0.52 g;61 %). 
M.P. 161-171°C; TLC-A: At 0.80; [aID25  (c=0.5, DMF) -2.0 0 ; FAB-MS: 
m/z=637 (6%), 191 (100); HRMS mlz 637.19346; CH29N409 requires 
637.19344; max(DMF)  278 nm (e=29, 000 mol -1 dm3cm -1 ); Vm (KBr disc) 
3300 (s, COOH, NH), 3040 (w, arom. CH str.), 2940 (w, aliph. CH str.), 1700 
(s, urethane 0=0), 1640 (s, amide), 1515 (s, C-NO2), 1340 cm -1 (s, C-NO2); 
8H (80 MHz, CDCI3) 8.1 (d, J=8Hz, 4H, Bnpeoc 3, 5H), 7.2-7.5 (m, 12H, 
Bnpeoc 2, 4H Dbse CH), 7.1 (s, 2H, CH=CH), 6.2 (d, J=9Hz, 1H, urethane 
NH), 4.5 (bm, 3H, Bnpeoc CHCH2), 4.3 (b, 2H, aCH, Dbs OH), 2.5 (m, 2H, 
f3CH2); Sc  (DMSO-d6) 171.1 (q, COOH), 168.2 (q, amide), 154.7 (q, 
urethane), 147.1-137.4 (4 peaks, q, arom.), 132.9-122.8 (7 peaks, CH 
aromatic), 64.8 (CH2, Bnpeoc), 53.6 (13CH2),  49.7 (aCH), 48.6 (CH, Fmoc), 
36.0 (OH, Dbse). 
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NaBenzyloxycarbonylLgl utamine (132) 
Z-Gln-OH 
This compound was prepared by the method of Beacham et a!166. To a 
cooled suspension of L-glutamine (36.5 g; 0.25 mol) in 1 M sodium 
hydrogen carbonate was added benzylchloroformate (37.5 cm 3 ; 0.26mo1) 
dropwise such that the reaction temperature did not exceed 5°C. The 
mixture was allowed to warm to room temperature then stirred for 20 h and 
extracted with diethyl ether (2x200 cm 3). The aqueous solution was 
carefully brought to pH=1 with 10 M HCI, keeping the temperature below 
5°C. The resulting white solid was recrystallised from water and dried in 
vacuo to give the title compound as a white solid (55.3 g; 70%). 
M.p. 138-139°C (lit. 166 139-141 0C); TLC-B Rf 0.62; kmax (THF) 257 nm 
(E=220 molldm 3cm 1 ); Vmax  (nujol mull) 3470 (s, COOH, NH), 3330 (s, NH), 
1690 (s, urethane C=O), 1620 (s, amide), 1530 cm -1 (s); oH (80 MHz, 
MeOH-d4) 7.5 (d, J=8Hz, 1H, amide NH), 7.3 (bs, 5H, Z aromatic CH), 6.8 
(b, urethane NH), 5.0 (s, 2H, benzylic CH2), 4.1 (b, 1H, aCH), 2.2 (m, 2H, 




This compound was prepared by the method of Konig and Geiger 123 . To a 
solution of NabenzyloxycarbonylLglutamine (11.2 g, 0.04 mol) and 4,4'-
dimethoxybenzhydrol (9.6 g, 0.04 mol) in acetic acid was added conc. 
sulphuric acid (0.5 cm 3) giving an orange solution. After stirring for 20 h the 
solution was poured into water (250 cm 3). The mixture was filtered and the 
solid washed with water, then taken up in EtOAc (100 cm 3). This solution 
was dried over anhydrous magnesium sulphate then concentrated in vacuo 
to a yellow oil. Trituration with diethyl ether and recrystallisation of the 
resulting solid from THF/ light petroleum gave the title compound as a white 
solid (13.0 g; 64%). 
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M.P. 119-120°C (lit. 123 117-120 0C); TLC-A Rf 0.76; FAB-MS m/z= 507 
(12%), 227 (100); HRMS m/z 507.21314; C23H30N207 requires 507.21311; 
Xmax (THE) 275 nm(e=9, 900 mol 1 dm3cm 1 ); vm  (KBr disc) 3300 (s, 
COOH, NH), 3070 (w, arom. CH str.), 2970 (w, aliph. CH str.), 1690 (s, 
urethane C=O), 1640 (s, amide), 1540 (s), 1510 (s), 1240 cm -1 (s); oH (80 
MHz, DMSO-d6) 8.6 (d, J=9Hz, 1H, amide NH), 7.4 (bs, 5H, Z aromatic 
CH), 7.2, 6.8 (AB, J=8Hz, 8H, Mbh aromatic), 6.0 (d, J=5Hz, 1H, urethane 
NH), 5.0 (s, 2H, benzylic CH2), 4.0 (b, 1H, aCH), 3.7 (s, 6H, OMe),2.2 (m, 
2H, yCH2), 1.8 (m, 2H, 13CH2). 
Ny-Bis(4-methoxyphenyl)methyl-L-glutamlne (134) 
H-GIn- ( Mbh )-OH 
This compound was prepared by the method of Konig and Geiger 123. A 
solution 	of 	NabenzyloxycarbonylN'Ybis(4methoxyphenyl) methyl-L- 
glutamine (13.0 g, 25.6 mmol) in THF (50 cm 3) was cooled to -78°C and 
flushed with dry nitrogen during the addition of 10% palladium on carbon 
(0.65 g; 5% by weight). The flask was evacuated then placed under 1 atm. 
hydrogen gas for 48 h. Glacial acetic acid (100 cm 3) was added to dissolve 
a white precipitate and the resulting suspension filtered through celite and 
concentrated to an oil. Trituration with diethyl ether gave a pale brown solid 
which was recrystallised from water and dried to give the title compound 
(7.77 g; 82%). 
M.P. 190-192°C (lit. 123 205-2060C); TLC-A Rf 0.35; FAB-MS m/z= 373 
(10%), 227 (100); HAMS m/z 373.17631; C20HN205 requires 373.17633; 
0H (80 MHz, DMSO-d6/CD3C000 1:1) 7.2, 6.8 (AB, J=8Hz, 8H, Mbh 
aromatic), 6.0 (s, 1H, Mbh CH), 4.0 (b, 1H, aCH), 3.7 (s, 6H, OMe), 2.3 (m, 





To a suspension of NY-bis(4-methoxyphenyl)-methyl-L-glutamine (4.0 g, 
10.8 mmol) in 10% aqueous sodium carbonate (150 cm 3) and dimethoxy-
ethane (80 cm3) was added a solution of N-(9-fluorenylmethoxycarbonyl)-O-
succinimide (5.6 g, 16.2 mmol) in dimethoxyethane (40 cm 3). The resulting 
solution was stirred for 20 h then diluted with water (200 cm 3) and extracted 
with diethyl ether (2x250 cm 3) and EtOAc (2x250 cm 3). The aqueous 
solution was carefully acidified with 2 M potassium hydrogensulphate and 
extracted with EtOAc (2x300 cm3). The organic extracts were dried over 
anhydrous magnesium sulphate then concentrated to Ca. 10 cm3 and 
passed down a column of silica (60H; 15 cm diam. x 15 cm deep) eluted 
with a gradient of methanol in chloroform (0-20%, total volume 1.5 dm 3). 
The appropriate fractions were combined and concentrated to Ca. 15 cm3 
then pipetted slowly into cold, stirred light petroleum (1 dm 3). The resulting 
white precipitate was filtered and dried to give the title compound (3.8 g; 
58%). 
M.p. 155-160°C (lit. 123 158-164°C); TLC-A Rf 0.75; [a]D25  (c=1.0, DMF) - 
8.90 ;FAB-MS m/z= 586 (13%), 227 (100); k max (THF) 262 (e17, 000), 300 
nm (5000 mol -1 dm3cm-1 ); 5H  (80 MHz, DMSO-d6) 8.7 (d, J=8Hz, 1H, amide 
NH), 7.0-7.8 (m, 16H, Fmoc and Mbh aromatic CH), 6.0 (m, 2H, urethane 
NH, Mbh CH), 4.3 (b, 3H, Fmoc CHCH2), 4.1 (b, 1H, aCH), 3.7 (s, 6H, 
OMe), 2.2 (m, 2H, CH2),1.9 (m, 2H, f3CH2). 
Na_BenzyIoxycarbonyINTtriphenylmethyIL.asparagine (136) 
Z-Asn-(Trt)-OH 
This compound was prepared by the method of Sieber and Riniker 156. To a 
solution of N°-benzyloxycarbonyl-L-asparagine (10.6 g, 0.04mol) and 
triphenylmethanol (20.8 g, 0.08mol) in acetic acid (120 cm 3) was added 
acetic anhydride (7.5 cm3, 0.08mol) and conc. sulphuric acid (0.5 cm 3). 
The resulting solution was heated to 50°C for 90 minutes then treated with 
water (100 cm 3) and EtOAc (200 cm 3). After separation the aqueous 
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solution was further extracted with EtOAc (200 cm 3). The combined organic 
extracts were washed with water (200 cm 3) and brine (200 cm3) then dried 
over anhydrous magnesium sulphate and concentrated to an oil. Trituration 
with diethyl ether gave a pale brown solid which was recrystallised from 
THF/diethyl ether to give the title compound as a white solid (6.8 g, 55%). 
M.p. 192-193°C (ljt. 156 195-1960C); TLC-A Rf 0.76; FAB-MS m/z= 509 
(40%), 243 (100); kmax (THF) 260 nm (e=930 mol -ldm3cm-1 ); 8H  (80 MHz, 
CDCI3) 8.5 (d, J=9Hz, 1H, amide NH), 7.3 (bs, 5H, Z aromatic CH), 7.1 (s, 




This compound was prepared by the method of Sieber and Riniker 156. A 
solution of (9.3 g, 
18.2 mmol) in THE (150 cm 3) and methanol(150 cm 3) was cooled to -78°C 
and flushed with dry nitrogen during the addition of 10% palladium on 
carbon (0.47 g; 5% by weight). The flask was evacuated then placed under 
1 atm. hydrogen gas for 72 h. The resulting suspension was filtered 
through celite and concentrated to an oil'. Trituration with diethyl ether gave 
a white solid which was recrystallised from water and dried to give the title 
compound (5.24 g; 77%). 
M.p. >220°C (lit. 156 >2200C); TLC-A Rf 0.20; EAB-MS m/z= 375 (7%), 243 
(100); 3H  (80 MHz, DMSO-d6) 8.6 (d, J=5Hz, 1H, amide NH), 7.1(s, 15H, 
trityl CH, 4.3 (b, 1 H, cxCH), 2.3 (m, 2H, f3CH2). 
NL.9FI uorenyl methoxycarbonyl-Ni-triphenyl methyl-L-asparagine (138) 
Fmoc-Asn-(Trt)-OH 
To a suspension of NT-tnphenylmethyl-L-asparagine (4.9 g, 13.1 mmol) in 
water (60 cm3) was added a solution of triethylamine (4.6 cm 3; 33 mmol) in 
dioxan (60 cm3). To the resulting solution was added N-(9-
fluorenylmethoxycarbonyl)-O-succinimide (4.5 g, 13.1 mmol). The resulting 
jp;e] 
solution was stirred for 12 h then diluted with water (150 cm 3), acidified with 
2 M potassium hydrogensulphate and extracted with EtOAc (2x300 cm 3). 
The organic extracts were washed with water (200 cm 3) and brine (200 
cm3), dried over anhydrous magnesium sulphate then concentrated to Ca. 
10 cm3 and passed in three portions down a column of silica (60H; 7.5 cm 
diarn. x 15 cm deep) eluted with a gradient of methanol in chloroform (0-
10%, total volume 400 cm 3). The appropriate fractions were combined and 
concentrated to Ca. 15 cm3 then pipetted slowly into cold, stirred light 
petroleum (1dm 3). The resulting white precipitate was filtered and dried to 
give the title compound (4.6 g; 60%). 
M.P. 180-187°C (ljt. 156 211-2130C); TLC-A Rf 0.66; [aID 25  (c=1.0, DMF) -9.8 
(lit. 156 -14.8°); FAB-MS m/z= 611(7%), 243 (100); Vm (KBr disc) 3300 (s, 
000H, NH), 3040 (w, arom. CH str.), 2940 (w, aliph. OH str.), 1690 (s, 
urethane 0=0), 1640 (s, amide), 1560 (s), 1480 (s), 1320 (rn), 730 (s), 690 
cm-1 (s); kmax (THF) 268 nm (e=17, 000 mol 1 dm3cm 1 ); oH  (80 MHz, ODd3) 
7.0-7.8 (m, 23H, Fmoc and Trt aromatic OH), 6.3 (b, 1H, urethane NH), 4.3 
(bm, 4H, Fmoc CHCH2, uGH), 2.7 (m, 2H, 13CH2). 
Coupling of Fmoc-GI n/Asn-(Dbse/Dbsa)-OH 
To a stirred solution of DIG (0.5 M in DMF; 2.0 cm 3) and HOBt (0.5 M in 
DMF; 2.0 cm 3 ) in DMF (4 cm3) was added in small portions the protected 
amino acid (1.0 mmol). After 20 minutes the mixture was filtered and the 
filtrate transferred to an Applied Biosystems reagent cartridge. The 
activated amino acid was taken up to the activator vessel and the cycle 
continued as normal. 
Comparative Deprotection of Side-Chain-Amide Protecting Groups 
To the protected amino acid (20 mg) was added 95% TFA (1.2 cm 3). The 
mixture was quickly shaken to achieve dissolution, then analysed by TLC. 
Further analyses were performed at intervals of 5 minutes up to 15 minutes. 
The upper and lower limits for the half-reaction point (t½) were determined by 
estimating the intensities of the appropriate spots following elution of the 
plate (eluant A) and detection with ninhydrin. Rf: 0.4 (Fmoc-Gln-OH); 0.7- 
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0.8 (Fmoc-Gln-(PG)-OH). After 10 minutes reaction a portion of the reaction 
mixture (0.6 cm 3) was withdrawn, evaporated to dryness and triturated with 
diethyl ether to give a white solid, this solid was taken up in 
acetonitrile/water (1:1; 1 cm 3) and analysed by TLC. The amount of Fmoc-
Gin-OH was calculated from the estimated intensities of the appropriate 






ti nins) %Fmoc-Gin (t=10mins) 
100 
5-10 	 90 
0-5 100 
10-15 	 60 
Comparative Solubility of Asn/Gln Derivatives 
To stirred solvent (0.5 cm 3) was added small portions of a weighed amount 
of the protected amino acid until the added material would not dissolve. 
Weighing the remaining solid placed an upper limit on the solubility of that 
derivative. 
Upper limit of Solubility in 1 cm 3 of: 
Derivative DMF Dioxan/DMF (1:1) 
Fmoc-Asn-(Trt)-OH >0.2g >0.2g 
Fmoc-Gln-(Trt)-OH >0.2g >0.2g 
Fmoc-Asn-(Dbse)-OH 0.08g insol. 
Fmoc-Gln-(Dbse)-OH >0.2g <0.05g 
Bnpeoc-Asn-(Dbse)-OH >0.2g >0.2g 
Bnpeoc-Gln-(Dbse)-OH >0.2g >0.2g 
IL-1-3-pre 233-238 (139) 
Phe-Pro-Asn-Trp-Tyr-Leu-OH 
The initial resin was Fmoc-Leu-(0.55 mmol g 1 ; 1.00 g, 0.55 mmol). The 
side-chain amide group of asparagine was protected by the 
dibenzosuberenyl group (Fmoc-Asn-(Dbse)-OH). 	This asparagi ne 
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derivative was activated outwith the peptide synthesiser as described 
above. The weight of peptide-resin after chain assembly was 1.32g. Resin-
bound peptide (0.2 g) was treated for 1.5 h with a solution of 5% thioanisole, 
5% N-acetyltryptamine and 5% water in TFA (10 cm 3). The resulting 
solution was concentrated in vacuo to ca. 2 cm3, then treated with 
water/diethyl ether (1:1; 30 cm 3). After separation the aqueous extract was 
washed with two further portions of diethyl ether (2x15 cm 3) and purified in 
10 portions by preparative HPLC (11 cm. column; flow 10 cm 3/minute; 
gradient: (time, % acetonitrile) (0, 10), (20, 40), (21, 10)). Lyophilisation of 
the appropriate fractions gave the title compound as a white solid (0.035 g; 
34% by proportion from starting resin.. 
FAB-MS calculated for CHN809 m/z 839.0; observed 839.0; Analytical 
HPLC (gradient A) Rt 13.0 minutes; Amino acid analysis (acid hydrolysis; 18 
h)Asx1O.91,Pro1l.01, A1a22.07, Leu1l.05, Tyr10.98, Phe1l.04, Trp10.84. 
Substance P (140) 
H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 
Chain assembly of this peptide was repeated five times. On each occasion 
the glutamine residues were incorporated with different side-chain amide 
protecting group. Peptide-resin (0.4 g) was cleaved in each case for 90 
minutes with a solution of 5% thioanisole, 5% anisole, 5% 
ethyl methylsulphide and 5% water in TFA (10 cm 3) to give crude peptide 
(0.16-0.19 g). The crude peptide was analysed by FAB-MS. 
Relative Peak Intensity When Amide Protected By: 
m/z Dbse Dbsa Trt Unprotected 
1348 100 100 100 15 	(MH+) 
1234 55 55 15 100 (M-Arg+CH3CO)+ 
Note. Crude peptide prepared using Fmoc-Gln-(Mbh)-OH not 
analysed. 	 0 
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